Search

Your search keyword '"Ballinger, M"' showing total 307 results
Start Over Author "Ballinger, M"
Sorry, I don't understand your search. ×
307 results on '"Ballinger, M"'

2. Annual (2023) taxonomic update of RNA-directed RNA polymerase-encoding negative-sense RNA viruses (realm Riboviria: kingdom Orthornavirae: phylum Negarnaviricota)

Author

Kuhn, J, Abe, J, Adkins, S, Alkhovsky, S, Avsic-Zupanc, T, Ayllon, M, Bahl, J, Balkema-Buschmann, A, Ballinger, M, Baranwal, V, Beer, M, Bejerman, N, Bergeron, E, Biedenkopf, N, Blair, C, Blasdell, K, Blouin, A, Bradfute, S, Briese, T, Brown, P, Buchholz, U, Buchmeier, M, Bukreyev, A, Burt, F, Buttner, C, Calisher, C, Cao, M, Casas, I, Chandran, K, Charrel, R, Chaturvedi, K, Chooi, K, Crane, A, Bo, E, de la Torre, J, de Souza, W, de Swart, R, Debat, H, Dheilly, N, Di Paola, N, Di Serio, F, Dietzgen, R, Digiaro, M, Drexler, J, Duprex, W, Durrwald, R, Easton, A, Elbeaino, T, Ergunay, K, Feng, G, Firth, A, Fooks, A, Formenty, P, Freitas-Astua, J, Gago-Zachert, S, Garcia, M, Garcia-Sastre, A, Garrison, A, Gaskin, T, Gong, W, Gonzalez, J, de Bellocq, J, Griffiths, A, Groschup, M, Gunther, I, Gunther, S, Hammond, J, Hasegawa, Y, Hayashi, K, Hepojoki, J, Higgins, C, Hongo, S, Horie, M, Hughes, H, Hume, A, Hyndman, T, Ikeda, K, Jiang, D, Jonson, G, Junglen, S, Klempa, B, Klingstrom, J, Kondo, H, Koonin, E, Krupovic, M, Kubota, K, Kurath, G, Laenen, L, Lambert, A, Li, J, Liu, R, Lukashevich, I, Macdiarmid, R, Maes, P, Marklewitz, M, Marshall, S, Marzano, S, Mccauley, J, Mirazimi, A, Muhlberger, E, Nabeshima, T, Naidu, R, Natsuaki, T, Navarro, B, Navarro, J, Neriya, Y, Netesov, S, Neumann, G, Nowotny, N, Nunes, M, Ochoa-Corona, F, Okada, T, Palacios, G, Pallas, V, Papa, A, Paraskevopoulou, S, Parrish, C, Pauvolid-Correa, A, Paweska, J, Perez, D, Pfaff, F, Plemper, R, Postler, T, Rabbidge, L, Radoshitzky, S, Ramos-Gonzalez, P, Rehanek, M, Resende, R, Reyes, C, Rodrigues, T, Romanowski, V, Rubbenstroth, D, Rubino, L, Runstadler, J, Sabanadzovic, S, Sadiq, S, Salvato, M, Sasaya, T, Schwemmle, M, Sharpe, S, Shi, M, Shimomoto, Y, Sidharthan, V, Sironi, M, Smither, S, Song, J, Spann, K, Spengler, J, Stenglein, M, Takada, A, Takeyama, S, Tatara, A, Tesh, R, Thornburg, N, Tian, X, Tischler, N, Tomitaka, Y, Tomonaga, K, Tordo, N, Tu, C, Turina, M, Tzanetakis, I, Vaira, A, van den Hoogen, B, Vanmechelen, B, Vasilakis, N, Verbeek, M, von Bargen, S, Wada, J, Wahl, V, Walker, P, Waltzek, T, Whitfield, A, Wolf, Y, Xia, H, Xylogianni, E, Yanagisawa, H, Yano, K, Ye, G, Yuan, Z, Zerbini, F, Zhang, G, Zhang, S, Zhang, Y, Zhao, L, Okland, A, Kuhn J. H., Abe J., Adkins S., Alkhovsky S. V., Avsic-Zupanc T., Ayllon M. A., Bahl J., Balkema-Buschmann A., Ballinger M. J., Baranwal V. K., Beer M., Bejerman N., Bergeron E., Biedenkopf N., Blair C. D., Blasdell K. R., Blouin A. G., Bradfute S. B., Briese T., Brown P. A., Buchholz U. J., Buchmeier M. J., Bukreyev A., Burt F., Buttner C., Calisher C. H., Cao M., Casas I., Chandran K., Charrel R. N., Chaturvedi K. K., Chooi K. M., Crane A., Bo E. D., de la Torre J. C., de Souza W. M., de Swart R. L., Debat H., Dheilly N. M., Di Paola N., Di Serio F., Dietzgen R. G., Digiaro M., Drexler J. F., Duprex W. P., Durrwald R., Easton A. J., Elbeaino T., Ergunay K., Feng G., Firth A. E., Fooks A. R., Formenty P. B. H., Freitas-Astua J., Gago-Zachert S., Garcia M. L., Garcia-Sastre A., Garrison A. R., Gaskin T. R., Gong W., Gonzalez J. -P. J., de Bellocq J., Griffiths A., Groschup M. H., Gunther I., Gunther S., Hammond J., Hasegawa Y., Hayashi K., Hepojoki J., Higgins C. M., Hongo S., Horie M., Hughes H. R., Hume A. J., Hyndman T. H., Ikeda K., Jiang D., Jonson G. B., Junglen S., Klempa B., Klingstrom J., Kondo H., Koonin E. V., Krupovic M., Kubota K., Kurath G., Laenen L., Lambert A. J., Li J., Li J. -M., Liu R., Lukashevich I. S., MacDiarmid R. M., Maes P., Marklewitz M., Marshall S. H., Marzano S. -Y. L., McCauley J. W., Mirazimi A., Muhlberger E., Nabeshima T., Naidu R., Natsuaki T., Navarro B., Navarro J. A., Neriya Y., Netesov S. V., Neumann G., Nowotny N., Nunes M. R. T., Ochoa-Corona F. M., Okada T., Palacios G., Pallas V., Papa A., Paraskevopoulou S., Parrish C. R., Pauvolid-Correa A., Paweska J. T., Perez D. R., Pfaff F., Plemper R. K., Postler T. S., Rabbidge L. O., Radoshitzky S. R., Ramos-Gonzalez P. L., Rehanek M., Resende R. O., Reyes C. A., Rodrigues T. C. S., Romanowski V., Rubbenstroth D., Rubino L., Runstadler J. A., Sabanadzovic S., Sadiq S., Salvato M. S., Sasaya T., Schwemmle M., Sharpe S. R., Shi M., Shimomoto Y., Sidharthan V. K., Sironi M., Smither S., Song J. -W., Spann K. M., Spengler J. R., Stenglein M. D., Takada A., Takeyama S., Tatara A., Tesh R. B., Thornburg N. J., Tian X., Tischler N. D., Tomitaka Y., Tomonaga K., Tordo N., Tu C., Turina M., Tzanetakis I. E., Vaira A. M., van den Hoogen B., Vanmechelen B., Vasilakis N., Verbeek M., von Bargen S., Wada J., Wahl V., Walker P. J., Waltzek T. B., Whitfield A. E., Wolf Y. I., Xia H., Xylogianni E., Yanagisawa H., Yano K., Ye G., Yuan Z., Zerbini F. M., Zhang G., Zhang S., Zhang Y. -Z., Zhao L., Okland A. L., Kuhn, J, Abe, J, Adkins, S, Alkhovsky, S, Avsic-Zupanc, T, Ayllon, M, Bahl, J, Balkema-Buschmann, A, Ballinger, M, Baranwal, V, Beer, M, Bejerman, N, Bergeron, E, Biedenkopf, N, Blair, C, Blasdell, K, Blouin, A, Bradfute, S, Briese, T, Brown, P, Buchholz, U, Buchmeier, M, Bukreyev, A, Burt, F, Buttner, C, Calisher, C, Cao, M, Casas, I, Chandran, K, Charrel, R, Chaturvedi, K, Chooi, K, Crane, A, Bo, E, de la Torre, J, de Souza, W, de Swart, R, Debat, H, Dheilly, N, Di Paola, N, Di Serio, F, Dietzgen, R, Digiaro, M, Drexler, J, Duprex, W, Durrwald, R, Easton, A, Elbeaino, T, Ergunay, K, Feng, G, Firth, A, Fooks, A, Formenty, P, Freitas-Astua, J, Gago-Zachert, S, Garcia, M, Garcia-Sastre, A, Garrison, A, Gaskin, T, Gong, W, Gonzalez, J, de Bellocq, J, Griffiths, A, Groschup, M, Gunther, I, Gunther, S, Hammond, J, Hasegawa, Y, Hayashi, K, Hepojoki, J, Higgins, C, Hongo, S, Horie, M, Hughes, H, Hume, A, Hyndman, T, Ikeda, K, Jiang, D, Jonson, G, Junglen, S, Klempa, B, Klingstrom, J, Kondo, H, Koonin, E, Krupovic, M, Kubota, K, Kurath, G, Laenen, L, Lambert, A, Li, J, Liu, R, Lukashevich, I, Macdiarmid, R, Maes, P, Marklewitz, M, Marshall, S, Marzano, S, Mccauley, J, Mirazimi, A, Muhlberger, E, Nabeshima, T, Naidu, R, Natsuaki, T, Navarro, B, Navarro, J, Neriya, Y, Netesov, S, Neumann, G, Nowotny, N, Nunes, M, Ochoa-Corona, F, Okada, T, Palacios, G, Pallas, V, Papa, A, Paraskevopoulou, S, Parrish, C, Pauvolid-Correa, A, Paweska, J, Perez, D, Pfaff, F, Plemper, R, Postler, T, Rabbidge, L, Radoshitzky, S, Ramos-Gonzalez, P, Rehanek, M, Resende, R, Reyes, C, Rodrigues, T, Romanowski, V, Rubbenstroth, D, Rubino, L, Runstadler, J, Sabanadzovic, S, Sadiq, S, Salvato, M, Sasaya, T, Schwemmle, M, Sharpe, S, Shi, M, Shimomoto, Y, Sidharthan, V, Sironi, M, Smither, S, Song, J, Spann, K, Spengler, J, Stenglein, M, Takada, A, Takeyama, S, Tatara, A, Tesh, R, Thornburg, N, Tian, X, Tischler, N, Tomitaka, Y, Tomonaga, K, Tordo, N, Tu, C, Turina, M, Tzanetakis, I, Vaira, A, van den Hoogen, B, Vanmechelen, B, Vasilakis, N, Verbeek, M, von Bargen, S, Wada, J, Wahl, V, Walker, P, Waltzek, T, Whitfield, A, Wolf, Y, Xia, H, Xylogianni, E, Yanagisawa, H, Yano, K, Ye, G, Yuan, Z, Zerbini, F, Zhang, G, Zhang, S, Zhang, Y, Zhao, L, Okland, A, Kuhn J. H., Abe J., Adkins S., Alkhovsky S. V., Avsic-Zupanc T., Ayllon M. A., Bahl J., Balkema-Buschmann A., Ballinger M. J., Baranwal V. K., Beer M., Bejerman N., Bergeron E., Biedenkopf N., Blair C. D., Blasdell K. R., Blouin A. G., Bradfute S. B., Briese T., Brown P. A., Buchholz U. J., Buchmeier M. J., Bukreyev A., Burt F., Buttner C., Calisher C. H., Cao M., Casas I., Chandran K., Charrel R. N., Chaturvedi K. K., Chooi K. M., Crane A., Bo E. D., de la Torre J. C., de Souza W. M., de Swart R. L., Debat H., Dheilly N. M., Di Paola N., Di Serio F., Dietzgen R. G., Digiaro M., Drexler J. F., Duprex W. P., Durrwald R., Easton A. J., Elbeaino T., Ergunay K., Feng G., Firth A. E., Fooks A. R., Formenty P. B. H., Freitas-Astua J., Gago-Zachert S., Garcia M. L., Garcia-Sastre A., Garrison A. R., Gaskin T. R., Gong W., Gonzalez J. -P. J., de Bellocq J., Griffiths A., Groschup M. H., Gunther I., Gunther S., Hammond J., Hasegawa Y., Hayashi K., Hepojoki J., Higgins C. M., Hongo S., Horie M., Hughes H. R., Hume A. J., Hyndman T. H., Ikeda K., Jiang D., Jonson G. B., Junglen S., Klempa B., Klingstrom J., Kondo H., Koonin E. V., Krupovic M., Kubota K., Kurath G., Laenen L., Lambert A. J., Li J., Li J. -M., Liu R., Lukashevich I. S., MacDiarmid R. M., Maes P., Marklewitz M., Marshall S. H., Marzano S. -Y. L., McCauley J. W., Mirazimi A., Muhlberger E., Nabeshima T., Naidu R., Natsuaki T., Navarro B., Navarro J. A., Neriya Y., Netesov S. V., Neumann G., Nowotny N., Nunes M. R. T., Ochoa-Corona F. M., Okada T., Palacios G., Pallas V., Papa A., Paraskevopoulou S., Parrish C. R., Pauvolid-Correa A., Paweska J. T., Perez D. R., Pfaff F., Plemper R. K., Postler T. S., Rabbidge L. O., Radoshitzky S. R., Ramos-Gonzalez P. L., Rehanek M., Resende R. O., Reyes C. A., Rodrigues T. C. S., Romanowski V., Rubbenstroth D., Rubino L., Runstadler J. A., Sabanadzovic S., Sadiq S., Salvato M. S., Sasaya T., Schwemmle M., Sharpe S. R., Shi M., Shimomoto Y., Sidharthan V. K., Sironi M., Smither S., Song J. -W., Spann K. M., Spengler J. R., Stenglein M. D., Takada A., Takeyama S., Tatara A., Tesh R. B., Thornburg N. J., Tian X., Tischler N. D., Tomitaka Y., Tomonaga K., Tordo N., Tu C., Turina M., Tzanetakis I. E., Vaira A. M., van den Hoogen B., Vanmechelen B., Vasilakis N., Verbeek M., von Bargen S., Wada J., Wahl V., Walker P. J., Waltzek T. B., Whitfield A. E., Wolf Y. I., Xia H., Xylogianni E., Yanagisawa H., Yano K., Ye G., Yuan Z., Zerbini F. M., Zhang G., Zhang S., Zhang Y. -Z., Zhao L., and Okland A. L.

Abstract

In April 2023, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. The phylum was expanded by one new family, 14 new genera, and 140 new species. Two genera and 538 species were renamed. One species was moved, and four were abolished. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV

Published
2023

3. OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell Scoring on SP263-Stained Whole Imaging Slides from IMpower110

Author

Herbst, R.S., primary, Ruderman, D., additional, Conway, J., additional, Prizant, H., additional, Hennek, S., additional, Shamshoian, J., additional, Abel, J., additional, Montalto, M., additional, Beck, A., additional, Wapinski, I., additional, Molinero, L., additional, Amin, R., additional, Hoang, T., additional, Ballinger, M., additional, de Marinis, F., additional, Giaccone, G., additional, Jassem, J., additional, Giltnane, J., additional, Srivastava, M.K., additional, and Spigel, D.R., additional

Published
2023
Full Text
View/download PDF

4. MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC

Author

Felip, E., primary, Srivastava, M., additional, Reck, M., additional, Wakelee, H., additional, Altorki, N., additional, Vallieres, E., additional, Liersch, R., additional, Oizumi, S., additional, Tanaka, H., additional, Hamm, J.T., additional, Novello, S., additional, McCune, S., additional, Molinero, L., additional, McNally, V., additional, Morris, S., additional, Ballinger, M., additional, Li, H., additional, Zou, W., additional, Nabet, B.J., additional, Bennett, E., additional, Gitlitz, B.J., additional, and Zhou, C., additional

Published
2023
Full Text
View/download PDF

5. 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

Author

Felip, E., primary, Srivastava, M., additional, Reck, M., additional, Wakelee, H., additional, Altorki, N.K., additional, Vallieres, E., additional, Liersch, R., additional, Harada, M., additional, Tanaka, H., additional, Hamm, J.T., additional, McCune, S., additional, Bennett, E., additional, Gitlitz, B.J., additional, McNally, V.A., additional, Novello, S., additional, Ballinger, M., additional, Zou, W., additional, Nabet, B., additional, Das Thakur, M., additional, and Zhou, C., additional

Published
2022
Full Text
View/download PDF

7. 1212P IMpower010: Characterisation of patients (pts) with stage II-IIIA PD-L1 TC≥50% NSCLC who were disease-free at 5 years (5yDF) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after resection and adjuvant (adj) chemotherapy (chemo)

Author

Felip, E., Vallieres, E., Gologordko, O., Martinez-Marti, A., Zhou, C., Altorki, N.K., Rittmeyer, A., Chella, A., Reck, M., Schütte, W., Okada, M., Liersch, R., Teixeira, M.E., Bennett, E., Gitlitz, B.J., Srivastava, M., Ballinger, M., Zhu, C., Crama, L., and Wakelee, H.

Published
2024
Full Text
View/download PDF

9. Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials

Author

Mazieres, J, Rittmeyer, A, Gadgeel, S, Hida, T, Gandara, D, Cortinovis, D, Barlesi, F, Yu, W, Matheny, C, Ballinger, M, Park, K, Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis D, Barlesi F, Yu W, Matheny C, Ballinger M, Park K., Mazieres, J, Rittmeyer, A, Gadgeel, S, Hida, T, Gandara, D, Cortinovis, D, Barlesi, F, Yu, W, Matheny, C, Ballinger, M, Park, K, Mazieres J, Rittmeyer A, Gadgeel S, Hida T, Gandara DR, Cortinovis D, Barlesi F, Yu W, Matheny C, Ballinger M, and Park K.

Abstract

Introduction: The phase 2 POPLAR and phase 3 OAK studies of the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab in patients with previously treated advanced NSCLC revealed significant improvements in survival versus docetaxel (p = 0.04 and 0.0003, respectively). Longer follow-up permits evaluation of continued benefit of atezolizumab. This study reports the final overall survival (OS) and safety findings from both trials. Methods: POPLAR randomized 287 patients (atezolizumab, 144; docetaxel, 143) and OAK randomized 1225 patients (atezolizumab, 613; docetaxel, 612). The patients received atezolizumab (1200 mg fixed dose) or docetaxel (75 mg/m2) every 3 weeks. Efficacy and safety outcomes were evaluated. Results: A longer OS was observed in patients receiving atezolizumab versus docetaxel in POPLAR (median OS = 12.6 mo versus 9.7 mo; hazard ratio = 0.76, 95% confidence interval [CI]: 0.58–1.00) and OAK (median OS = 13.3 versus 9.8 mo; hazard ratio = 0.78, 95% CI: 0.68–0.89). The 4-year OS rates in POPLAR were 14.8% (8.7–20.8) and 8.1% (3.2–13.0) and those in OAK were 15.5% (12.4–18.7) and 8.7% (6.2–11.3) for atezolizumab and docetaxel, respectively. Atezolizumab had improved OS benefit compared with docetaxel across all PD-L1 expression and histology groups. Most 4-year survivors in the docetaxel arms received subsequent immunotherapy (POPLAR, 50%; OAK, 65%). Of the 4-year survivors, most had Eastern Cooperative Oncology Group performance status of 0 and nonsquamous histological classification and approximately half were responders (POPLAR: atezolizumab, seven of 15; docetaxel, three of four; OAK: atezolizumab, 24 of 43; docetaxel, 11 of 26). Treatment-related grade 3/4 adverse events occurred in 27% and 16% of atezolizumab 4-year survivors in POPLAR and OAK, respectively. Conclusions: Long-term follow-up suggests a consistent survival benefit with atezolizumab versus docetaxel in patients with previously treated NSCLC regardless of PD-L1 expression

Published
2021

11. 2022 taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales

Author

Kuhn, J, Adkins, S, Alkhovsky, S, Avšič-Županc, T, Ayllón, M, Bahl, J, Balkema-Buschmann, A, Ballinger, M, Bandte, M, Beer, M, Bejerman, N, Bergeron, É, Biedenkopf, N, Bigarré, L, Blair, C, Blasdell, K, Bradfute, S, Briese, T, Brown, P, Bruggmann, R, Buchholz, U, Buchmeier, M, Bukreyev, A, Burt, F, Büttner, C, Calisher, C, Candresse, T, Carson, J, Casas, I, Chandran, K, Charrel, R, Chiaki, Y, Crane, A, Crane, M, Dacheux, L, Bó, E, de la Torre, J, de Lamballerie, X, de Souza, W, de Swart, R, Dheilly, N, Di Paola, N, Di Serio, F, Dietzgen, R, Digiaro, M, Drexler, J, Duprex, W, Dürrwald, R, Easton, A, Elbeaino, T, Ergünay, K, Feng, G, Feuvrier, C, Firth, A, Fooks, A, Formenty, P, Freitas-Astúa, J, Gago-Zachert, S, García, M, García-Sastre, A, Garrison, A, Godwin, S, Gonzalez, J, de Bellocq, J, Griffiths, A, Groschup, M, Günther, S, Hammond, J, Hepojoki, J, Hierweger, M, Hongō, S, Horie, M, Horikawa, H, Hughes, H, Hume, A, Hyndman, T, Jiāng, D, Jonson, G, Junglen, S, Kadono, F, Karlin, D, Klempa, B, Klingström, J, Koch, M, Kondō, H, Koonin, E, Krásová, J, Krupovic, M, Kubota, K, Kuzmin, I, Laenen, L, Lambert, A, Lǐ, J, Li, J, Lieffrig, F, Lukashevich, I, Luo, D, Maes, P, Marklewitz, M, Marshall, S, Marzano, S, Mccauley, J, Mirazimi, A, Mohr, P, Moody, N, Morita, Y, Morrison, R, Mühlberger, E, Naidu, R, Natsuaki, T, Navarro, J, Neriya, Y, Netesov, S, Neumann, G, Nowotny, N, Ochoa-Corona, F, Palacios, G, Pallandre, L, Pallás, V, Papa, A, Paraskevopoulou, S, Parrish, C, Pauvolid-Corrêa, A, Pawęska, J, Pérez, D, Pfaff, F, Plemper, R, Postler, T, Pozet, F, Radoshitzky, S, Ramos-González, P, Rehanek, M, Resende, R, Reyes, C, Romanowski, V, Rubbenstroth, D, Rubino, L, Rumbou, A, Runstadler, J, Rupp, M, Sabanadzovic, S, Sasaya, T, Schmidt-Posthaus, H, Schwemmle, M, Seuberlich, T, Sharpe, S, Shi, M, Sironi, M, Smither, S, Song, J, Spann, K, Spengler, J, Stenglein, M, Takada, A, Tesh, R, Těšíková, J, Thornburg, N, Tischler, N, Tomitaka, Y, Tomonaga, K, Tordo, N, Tsunekawa, K, Turina, M, Tzanetakis, I, Vaira, A, van den Hoogen, B, Vanmechelen, B, Vasilakis, N, Verbeek, M, von Bargen, S, Wada, J, Wahl, V, Walker, P, Whitfield, A, Williams, J, Wolf, Y, Yamasaki, J, Yanagisawa, H, Ye, G, Zhang, Y, Økland, A, Kuhn JH, Adkins S, Alkhovsky SV, Avšič-Županc T, Ayllón MA, Bahl J, Balkema-Buschmann A, Ballinger MJ, Bandte M, Beer M, Bejerman N, Bergeron É, Biedenkopf N, Bigarré L, Blair CD, Blasdell KR, Bradfute SB, Briese T, Brown PA, Bruggmann R, Buchholz UJ, Buchmeier MJ, Bukreyev A, Burt F, Büttner C, Calisher CH, Candresse T, Carson J, Casas I, Chandran K, Charrel RN, Chiaki Y, Crane A, Crane M, Dacheux L, Bó ED, de la Torre JC, de Lamballerie X, de Souza WM, de Swart RL, Dheilly NM, Di Paola N, Di Serio F, Dietzgen RG, Digiaro M, Drexler JF, Duprex WP, Dürrwald R, Easton AJ, Elbeaino T, Ergünay K, Feng G, Feuvrier C, Firth AE, Fooks AR, Formenty PBH, Freitas-Astúa J, Gago-Zachert S, García ML, García-Sastre A, Garrison AR, Godwin SE, Gonzalez JJ, de Bellocq JG, Griffiths A, Groschup MH, Günther S, Hammond J, Hepojoki J, Hierweger MM, Hongō S, Horie M, Horikawa H, Hughes HR, Hume AJ, Hyndman TH, Jiāng D, Jonson GB, Junglen S, Kadono F, Karlin DG, Klempa B, Klingström J, Koch MC, Kondō H, Koonin EV, Krásová J, Krupovic M, Kubota K, Kuzmin IV, Laenen L, Lambert AJ, Lǐ J, Li JM, Lieffrig F, Lukashevich IS, Luo D, Maes P, Marklewitz M, Marshall SH, Marzano SL, McCauley JW, Mirazimi A, Mohr PG, Moody NJG, Morita Y, Morrison RN, Mühlberger E, Naidu R, Natsuaki T, Navarro JA, Neriya Y, Netesov SV, Neumann G, Nowotny N, Ochoa-Corona FM, Palacios G, Pallandre L, Pallás V, Papa A, Paraskevopoulou S, Parrish CR, Pauvolid-Corrêa A, Pawęska JT, Pérez DR, Pfaff F, Plemper RK, Postler TS, Pozet F, Radoshitzky SR, Ramos-González PL, Rehanek M, Resende RO, Reyes CA, Romanowski V, Rubbenstroth D, Rubino L, Rumbou A, Runstadler JA, Rupp M, Sabanadzovic S, Sasaya T, Schmidt-Posthaus H, Schwemmle M, Seuberlich T, Sharpe SR, Shi M, Sironi M, Smither S, Song JW, Spann KM, Spengler JR, Stenglein MD, Takada A, Tesh RB, Těšíková J, Thornburg NJ, Tischler ND, Tomitaka Y, Tomonaga K, Tordo N, Tsunekawa K, Turina M, Tzanetakis IE, Vaira AM, van den Hoogen B, Vanmechelen B, Vasilakis N, Verbeek M, von Bargen S, Wada J, Wahl V, Walker PJ, Whitfield AE, Williams JV, Wolf YI, Yamasaki J, Yanagisawa H, Ye G, Zhang YZ, Økland AL., Kuhn, J, Adkins, S, Alkhovsky, S, Avšič-Županc, T, Ayllón, M, Bahl, J, Balkema-Buschmann, A, Ballinger, M, Bandte, M, Beer, M, Bejerman, N, Bergeron, É, Biedenkopf, N, Bigarré, L, Blair, C, Blasdell, K, Bradfute, S, Briese, T, Brown, P, Bruggmann, R, Buchholz, U, Buchmeier, M, Bukreyev, A, Burt, F, Büttner, C, Calisher, C, Candresse, T, Carson, J, Casas, I, Chandran, K, Charrel, R, Chiaki, Y, Crane, A, Crane, M, Dacheux, L, Bó, E, de la Torre, J, de Lamballerie, X, de Souza, W, de Swart, R, Dheilly, N, Di Paola, N, Di Serio, F, Dietzgen, R, Digiaro, M, Drexler, J, Duprex, W, Dürrwald, R, Easton, A, Elbeaino, T, Ergünay, K, Feng, G, Feuvrier, C, Firth, A, Fooks, A, Formenty, P, Freitas-Astúa, J, Gago-Zachert, S, García, M, García-Sastre, A, Garrison, A, Godwin, S, Gonzalez, J, de Bellocq, J, Griffiths, A, Groschup, M, Günther, S, Hammond, J, Hepojoki, J, Hierweger, M, Hongō, S, Horie, M, Horikawa, H, Hughes, H, Hume, A, Hyndman, T, Jiāng, D, Jonson, G, Junglen, S, Kadono, F, Karlin, D, Klempa, B, Klingström, J, Koch, M, Kondō, H, Koonin, E, Krásová, J, Krupovic, M, Kubota, K, Kuzmin, I, Laenen, L, Lambert, A, Lǐ, J, Li, J, Lieffrig, F, Lukashevich, I, Luo, D, Maes, P, Marklewitz, M, Marshall, S, Marzano, S, Mccauley, J, Mirazimi, A, Mohr, P, Moody, N, Morita, Y, Morrison, R, Mühlberger, E, Naidu, R, Natsuaki, T, Navarro, J, Neriya, Y, Netesov, S, Neumann, G, Nowotny, N, Ochoa-Corona, F, Palacios, G, Pallandre, L, Pallás, V, Papa, A, Paraskevopoulou, S, Parrish, C, Pauvolid-Corrêa, A, Pawęska, J, Pérez, D, Pfaff, F, Plemper, R, Postler, T, Pozet, F, Radoshitzky, S, Ramos-González, P, Rehanek, M, Resende, R, Reyes, C, Romanowski, V, Rubbenstroth, D, Rubino, L, Rumbou, A, Runstadler, J, Rupp, M, Sabanadzovic, S, Sasaya, T, Schmidt-Posthaus, H, Schwemmle, M, Seuberlich, T, Sharpe, S, Shi, M, Sironi, M, Smither, S, Song, J, Spann, K, Spengler, J, Stenglein, M, Takada, A, Tesh, R, Těšíková, J, Thornburg, N, Tischler, N, Tomitaka, Y, Tomonaga, K, Tordo, N, Tsunekawa, K, Turina, M, Tzanetakis, I, Vaira, A, van den Hoogen, B, Vanmechelen, B, Vasilakis, N, Verbeek, M, von Bargen, S, Wada, J, Wahl, V, Walker, P, Whitfield, A, Williams, J, Wolf, Y, Yamasaki, J, Yanagisawa, H, Ye, G, Zhang, Y, Økland, A, Kuhn JH, Adkins S, Alkhovsky SV, Avšič-Županc T, Ayllón MA, Bahl J, Balkema-Buschmann A, Ballinger MJ, Bandte M, Beer M, Bejerman N, Bergeron É, Biedenkopf N, Bigarré L, Blair CD, Blasdell KR, Bradfute SB, Briese T, Brown PA, Bruggmann R, Buchholz UJ, Buchmeier MJ, Bukreyev A, Burt F, Büttner C, Calisher CH, Candresse T, Carson J, Casas I, Chandran K, Charrel RN, Chiaki Y, Crane A, Crane M, Dacheux L, Bó ED, de la Torre JC, de Lamballerie X, de Souza WM, de Swart RL, Dheilly NM, Di Paola N, Di Serio F, Dietzgen RG, Digiaro M, Drexler JF, Duprex WP, Dürrwald R, Easton AJ, Elbeaino T, Ergünay K, Feng G, Feuvrier C, Firth AE, Fooks AR, Formenty PBH, Freitas-Astúa J, Gago-Zachert S, García ML, García-Sastre A, Garrison AR, Godwin SE, Gonzalez JJ, de Bellocq JG, Griffiths A, Groschup MH, Günther S, Hammond J, Hepojoki J, Hierweger MM, Hongō S, Horie M, Horikawa H, Hughes HR, Hume AJ, Hyndman TH, Jiāng D, Jonson GB, Junglen S, Kadono F, Karlin DG, Klempa B, Klingström J, Koch MC, Kondō H, Koonin EV, Krásová J, Krupovic M, Kubota K, Kuzmin IV, Laenen L, Lambert AJ, Lǐ J, Li JM, Lieffrig F, Lukashevich IS, Luo D, Maes P, Marklewitz M, Marshall SH, Marzano SL, McCauley JW, Mirazimi A, Mohr PG, Moody NJG, Morita Y, Morrison RN, Mühlberger E, Naidu R, Natsuaki T, Navarro JA, Neriya Y, Netesov SV, Neumann G, Nowotny N, Ochoa-Corona FM, Palacios G, Pallandre L, Pallás V, Papa A, Paraskevopoulou S, Parrish CR, Pauvolid-Corrêa A, Pawęska JT, Pérez DR, Pfaff F, Plemper RK, Postler TS, Pozet F, Radoshitzky SR, Ramos-González PL, Rehanek M, Resende RO, Reyes CA, Romanowski V, Rubbenstroth D, Rubino L, Rumbou A, Runstadler JA, Rupp M, Sabanadzovic S, Sasaya T, Schmidt-Posthaus H, Schwemmle M, Seuberlich T, Sharpe SR, Shi M, Sironi M, Smither S, Song JW, Spann KM, Spengler JR, Stenglein MD, Takada A, Tesh RB, Těšíková J, Thornburg NJ, Tischler ND, Tomitaka Y, Tomonaga K, Tordo N, Tsunekawa K, Turina M, Tzanetakis IE, Vaira AM, van den Hoogen B, Vanmechelen B, Vasilakis N, Verbeek M, von Bargen S, Wada J, Wahl V, Walker PJ, Whitfield AE, Williams JV, Wolf YI, Yamasaki J, Yanagisawa H, Ye G, Zhang YZ, and Økland AL.

Abstract

In March 2022, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. The phylum was expanded by two new families (bunyaviral Discoviridae and Tulasviridae), 41 new genera, and 98 new species. Three hundred forty-nine species were renamed and/or moved. The accidentally misspelled names of seven species were corrected. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV.

Published
2022

12. Validation of the multidimensional impact of Cancer Risk Assessment Questionnaire to assess impact of waiting for genome sequencing results.

Author

Best, M, Napier, C, Schlub, T, Bartley, N, Biesecker, B, Ballinger, M, Butow, P, Best, M, Napier, C, Schlub, T, Bartley, N, Biesecker, B, Ballinger, M, and Butow, P

Abstract

OBJECTIVE: To determine whether the existing Multidimensional Impact of Cancer Risk Assessment (MICRA) scale, which assesses impact of receiving genetic test results on individuals being assessed for cancer risk, can be successfully adapted to cancer patients experiencing prolonged waiting for results of germline genome sequencing (GS). METHODS: Patients previously diagnosed with likely hereditary cancer (n = 250) who were waiting for germline GS results completed questionnaires 3 months after baseline. We adapted the MICRA to measure anxiety associated with waiting for results, and assessed factor structure, internal consistency, test-retest reliability and construct validation. RESULTS: Factor analysis revealed four factors: distress, positive experience, family support and uncertainty. Internal consistency for each sub-scale was high with the values of Cronbach's alpha for the distress, positive experiences, family support and uncertainty sub-scales 0.92, 0.88, 0.92 and 0.87, respectively. Test-retest reliability was poor, with intra-class correlations of 0.53, 0.13, 0.33 and 0.52 for the four factors, respectively. Construct validation showed large correlations between the MICRA distress and uncertainty sub-scale scores and the Impact of Events score intrusion (0.42 and 0.62, respectively) and IES avoidant thinking sub-scales (0.40 and 0.58, respectively) but not the Hospital Anxiety and Depression Scale sub-scales. CONCLUSIONS: The adapted MICRA identified test-related anxiety and uncertainty in a population of cancer patients waiting for germline GS results. Results suggest that the distress and uncertainty sub-scales of the adapted measure are most useful in this context.

Published
2022

13. 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

Author

Zhou, C., primary, Das Thakur, M., additional, Srivastava, M.K., additional, Zou, W., additional, Xu, H., additional, Ballinger, M., additional, Felip, E., additional, Wakelee, H., additional, Altorki, N.K., additional, Reck, M., additional, Liersch, R., additional, Kryzhanivska, A., additional, Harada, M., additional, Tanaka, H., additional, Hamm, J., additional, McCune, S., additional, McNally, V., additional, Bennett, E., additional, Gitlitz, B., additional, and Novello, S., additional

Published
2021
Full Text
View/download PDF

14. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study

Author

Gadgeel, S, Lukas, R, Goldschmidt, J, Conkling, P, Park, K, Cortinovis, D, de Marinis, F, Rittmeyer, A, Patel, J, von Pawel, J, O'Hear, C, Lai, C, Hu, S, Ballinger, M, Sandler, A, Gandhi, M, Fehrenbacher, L, Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O'Hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L., Gadgeel, S, Lukas, R, Goldschmidt, J, Conkling, P, Park, K, Cortinovis, D, de Marinis, F, Rittmeyer, A, Patel, J, von Pawel, J, O'Hear, C, Lai, C, Hu, S, Ballinger, M, Sandler, A, Gandhi, M, Fehrenbacher, L, Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O'Hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, and Fehrenbacher L.

Abstract

Objectives: To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods: Patients received 1200 mg atezolizumab or 75 mg/m2 docetaxel every 3 weeks until unacceptable toxicity, disease progression, or loss of clinical atezolizumab benefit. Patients with asymptomatic, treated supratentorial metastases were eligible. Patients had brain scans before enrollment; follow-up brain scans and treatment were required when clinically indicated. Results: Approximately 14% of patients in each arm had a history of asymptomatic, treated brain metastases (61/425 in the atezolizumab arm and 62/425 in the docetaxel arm). Fewer treatment-related adverse events (AEs), serious AEs, and treatment-related neurologic AEs were reported with atezolizumab than with docetaxel, regardless of history of asymptomatic, treated brain metastases. In patients with a history of asymptomatic, treated brain metastases, median overall survival (OS) was longer with atezolizumab than with docetaxel (16.0 vs 11.9 months; hazard ratio = 0.74; 95% CI: 0.49–1.13). Median OS was also longer with atezolizumab in patients without a history of asymptomatic, treated brain metastases (13.2 vs 9.3 months; hazard ratio = 0.74; 95% CI: 0.63–0.88). Landmark analyses showed that patients with a history of asymptomatic, treated brain metastases had a lower probability of developing new symptomatic brain lesions with atezolizumab vs docetaxel at 6–24 months. Patients without a history had a lower probability with atezolizumab at 18–24+ months. Conclusion: Atezolizumab had an acceptable neurologic safety profile, showed a trend toward an OS benefit, and led to a prolonged time to radiographic identification of new symptomatic brain lesions compared with docetaxel in patients who had a history of asymptomatic, treated brain metastases. Clinicaltrials.gov registration number: NCT02008227.

Published
2019

17. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

Author

Gandara, D., Reck, M., Moro-Sibilot, D., Mazieres, J., Gadgeel, S., Morris, S., Cardona, A., Mendus, D., Ballinger, M., Rittmeyer, A., and Peters, S.

Subjects
immunotherapy, lung neoplasms
Abstract

Treatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to develop clinically relevant and applicable criteria for fast progression (FP), incorporating tumor growth kinetics and early death from disease progression to analyze data from the randomized phase III OAK study. The OAK study evaluated the efficacy and safety of atezolizumab versus docetaxel as second-line or third-line treatment for stage IIIb/IV non-small cell lung cancer. FP rates and associated baseline factors were analyzed. FP was defined as either a ≥50% increase in the sum of largest diameters (SLDs) within 6 weeks of treatment initiation or death due to cancer progression within 12 weeks (absent post-baseline scan). Forty-two of 421 patients (10%) receiving atezolizumab and 37 of 402 (9%) receiving docetaxel had FP. Twenty patients with FP (48%) receiving atezolizumab versus 12 (30%) receiving docetaxel had a ≥50% SLD increase within 6 weeks. FP was significantly associated with an ECOG (Eastern Cooperative Oncology Group) performance status of 1 (vs 0), ≥3 metastatic sites at baseline, and failure of preceding first-line treatment within 6 months, but not with epidermal growth factor receptor mutation, programmed cell death 1 ligand 1 or tumor mutational burden. Overall survival in patients with FP and a ≥50% SLD increase at week 6 was similar with atezolizumab and docetaxel (unstratified HR 0.89 (95% CI 0.41 to 1.92)). FP rates were similar with atezolizumab and docetaxel in the OAK study, suggesting that FP may not be unique to checkpoint inhibitors, although the underlying mechanisms may differ from those of chemotherapy. Applying the FP criteria to other phase III checkpoint inhibitor trials may further elucidate the risk factors for FP. NCT02008227.

Published
2021

18. 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales

Author

Kuhn, J, Adkins, S, Agwanda, B, Al Kubrusli, R, Alkhovsky, S, Amarasinghe, G, Avsic-Zupanc, T, Ayllon, M, Bahl, J, Balkema-Buschmann, A, Ballinger, M, Basler, C, Bavari, S, Beer, M, Bejerman, N, Bennett, A, Bente, D, Bergeron, E, Bird, B, Blair, C, Blasdell, K, Blystad, D, Bojko, J, Borth, W, Bradfute, S, Breyta, R, Briese, T, Brown, P, Brown, J, Buchholz, U, Buchmeier, M, Bukreyev, A, Burt, F, Buttner, C, Calisher, C, Cao, M, Casas, I, Chandran, K, Charrel, R, Cheng, Q, Chiaki, Y, Chiapello, M, Choi, I, Ciuffo, M, Clegg, J, Crozier, I, Dal Bo, E, de la Torre, J, de Lamballerie, X, de Swart, R, Debat, H, Dheilly, N, Di Cicco, E, Di Paola, N, Di Serio, F, Dietzgen, R, Digiaro, M, Dolnik, O, Drebot, M, Drexler, J, Dundon, W, Duprex, W, Durrwald, R, Dye, J, Easton, A, Ebihara, H, Elbeaino, T, Ergunay, K, Ferguson, H, Fooks, A, Forgia, M, Formenty, P, Franova, J, Freitas-Astua, J, Fu, J, Furl, S, Gago-Zachert, S, Gao, G, Garcia, M, Garcia-Sastre, A, Garrison, A, Gaskin, T, Gonzalez, J, Griffiths, A, Goldberg, T, Groschup, M, Gunther, S, Hall, R, Hammond, J, Han, T, Hepojoki, J, Hewson, R, Hong, J, Hong, N, Hongo, S, Horie, M, Hu, J, Hu, T, Hughes, H, Huttner, F, Hyndman, T, Ilyas, M, Jalkanen, R, Jiang, D, Jonson, G, Junglen, S, Kadono, F, Kaukinen, K, Kawate, M, Klempa, B, Klingstrom, J, Kobinger, G, Koloniuk, I, Kondo, H, Koonin, E, Krupovic, M, Kubota, K, Kurath, G, Laenen, L, Lambert, A, Langevin, S, Lee, B, Lefkowitz, E, Leroy, E, Li, S, Li, L, Li, J, Liu, H, Lukashevich, I, Maes, P, de Souza, W, Marklewitz, M, Marshall, S, Marzano, S, Massart, S, Mccauley, J, Melzer, M, Mielke-Ehret, N, Miller, K, Ming, T, Mirazimi, A, Mordecai, G, Muhlbach, H, Muhlberger, E, Naidu, R, Natsuaki, T, Navarro, J, Netesov, S, Neumann, G, Nowotny, N, Nunes, M, Olmedo-Velarde, A, Palacios, G, Pallas, V, Palyi, B, Papa, A, Paraskevopoulou, S, Park, A, Parrish, C, Patterson, D, Pauvolid-Correa, A, Paweska, J, Payne, S, Peracchio, C, Perez, D, Postler, T, Qi, L, Radoshitzky, S, Resende, R, Reyes, C, Rima, B, Luna, G, Romanowski, V, Rota, P, Rubbenstroth, D, Rubino, L, Runstadler, J, Sabanadzovic, S, Sall, A, Salvato, M, Sang, R, Sasaya, T, Schulze, A, Schwemmle, M, Shi, M, Shi, X, Shi, Z, Shimomoto, Y, Shirako, Y, Siddell, S, Simmonds, P, Sironi, M, Smagghe, G, Smither, S, Song, J, Spann, K, Spengler, J, Stenglein, M, Stone, D, Sugano, J, Suttle, C, Tabata, A, Takada, A, Takeuchi, S, Tchouassi, D, Teffer, A, Tesh, R, Thornburg, N, Tomitaka, Y, Tomonaga, K, Tordo, N, Torto, B, Towner, J, Tsuda, S, Tu, C, Turina, M, Tzanetakis, I, Uchida, J, Usugi, T, Vaira, A, Vallino, M, van den Hoogen, B, Varsani, A, Vasilakis, N, Verbeek, M, von Bargen, S, Wada, J, Wahl, V, Walker, P, Wang, L, Wang, G, Wang, Y, Waqas, M, Wei, T, Wen, S, Whitfield, A, Williams, J, Wolf, Y, Wu, J, Xu, L, Yanagisawa, H, Yang, C, Yang, Z, Zerbini, F, Zhai, L, Zhang, Y, Zhang, S, Zhang, J, Zhang, Z, Zhou, X, Kuhn JH, Adkins S, Agwanda BR, Al Kubrusli R, Alkhovsky SV, Amarasinghe GK, Avsic-Zupanc T, Ayllon MA, Bahl J, Balkema-Buschmann A, Ballinger MJ, Basler CF, Bavari S, Beer M, Bejerman N, Bennett AJ, Bente DA, Bergeron E, Bird BH, Blair CD, Blasdell KR, Blystad DR, Bojko J, Borth WB, Bradfute S, Breyta R, Briese T, Brown PA, Brown JK, Buchholz UJ, Buchmeier MJ, Bukreyev A, Burt F, Buttner C, Calisher CH, Cao MJ, Casas I, Chandran K, Charrel RN, Cheng Q, Chiaki Y, Chiapello M, Choi I, Ciuffo M, Clegg JCS, Crozier I, Dal Bo E, de la Torre JC, de Lamballerie X, de Swart RL, Debat H, Dheilly NM, Di Cicco E, Di Paola N, Di Serio F, Dietzgen RG, Digiaro M, Dolnik O, Drebot MA, Drexler JF, Dundon WG, Duprex WP, Durrwald R, Dye JM, Easton AJ, Ebihara H, Elbeaino T, Ergunay K, Ferguson HW, Fooks AR, Forgia M, Formenty PBH, Franova J, Freitas-Astua J, Fu JJ, Furl S, Gago-Zachert S, Gao GF, Garcia ML, Garcia-Sastre A, Garrison AR, Gaskin T, Gonzalez JPJ, Griffiths A, Goldberg TL, Groschup MH, Gunther S, Hall RA, Hammond J, Han T, Hepojoki J, Hewson R, Hong J, Hong N, Hongo S, Horie M, Hu JS, Hu T, Hughes HR, Huttner F, Hyndman TH, Ilyas M, Jalkanen R, Jiang DH, Jonson GB, Junglen S, Kadono F, Kaukinen KH, Kawate M, Klempa B, Klingstrom J, Kobinger G, Koloniuk I, Kondo H, Koonin EV, Krupovic M, Kubota K, Kurath G, Laenen L, Lambert AJ, Langevin SL, Lee B, Lefkowitz EJ, Leroy EM, Li SR, Li LH, Li JR, Liu HZ, Lukashevich IS, Maes P, de Souza WM, Marklewitz M, Marshall SH, Marzano SYL, Massart S, McCauley JW, Melzer M, Mielke-Ehret N, Miller KM, Ming TJ, Mirazimi A, Mordecai GJ, Muhlbach HP, Muhlberger E, Naidu R, Natsuaki T, Navarro JA, Netesov SV, Neumann G, Nowotny N, Nunes MRT, Olmedo-Velarde A, Palacios G, Pallas V, Palyi B, Papa A, Paraskevopoulou S, Park AC, Parrish CR, Patterson DA, Pauvolid-Correa A, Paweska JT, Payne S, Peracchio C, Perez DR, Postler TS, Qi LY, Radoshitzky SR, Resende RO, Reyes CA, Rima BK, Luna GR, Romanowski V, Rota P, Rubbenstroth D, Rubino L, Runstadler JA, Sabanadzovic S, Sall AA, Salvato MS, Sang RS, Sasaya T, Schulze AD, Schwemmle M, Shi M, Shi XH, Shi ZL, Shimomoto Y, Shirako Y, Siddell SG, Simmonds P, Sironi M, Smagghe G, Smither S, Song JW, Spann K, Spengler JR, Stenglein MD, Stone DM, Sugano J, Suttle CA, Tabata A, Takada A, Takeuchi S, Tchouassi DP, Teffer A, Tesh RB, Thornburg NJ, Tomitaka Y, Tomonaga K, Tordo N, Torto B, Towner JS, Tsuda S, Tu CC, Turina M, Tzanetakis IE, Uchida J, Usugi T, Vaira AM, Vallino M, van den Hoogen B, Varsani A, Vasilakis N, Verbeek M, von Bargen S, Wada J, Wahl V, Walker PJ, Wang LF, Wang GP, Wang YX, Wang YQ, Waqas M, Wei TY, Wen SH, Whitfield AE, Williams JV, Wolf YI, Wu JX, Xu L, Yanagisawa H, Yang CX, Yang ZK, Zerbini FM, Zhai L, Zhang YZ, Zhang S, Zhang JG, Zhang Z, Zhou XP, Kuhn, J, Adkins, S, Agwanda, B, Al Kubrusli, R, Alkhovsky, S, Amarasinghe, G, Avsic-Zupanc, T, Ayllon, M, Bahl, J, Balkema-Buschmann, A, Ballinger, M, Basler, C, Bavari, S, Beer, M, Bejerman, N, Bennett, A, Bente, D, Bergeron, E, Bird, B, Blair, C, Blasdell, K, Blystad, D, Bojko, J, Borth, W, Bradfute, S, Breyta, R, Briese, T, Brown, P, Brown, J, Buchholz, U, Buchmeier, M, Bukreyev, A, Burt, F, Buttner, C, Calisher, C, Cao, M, Casas, I, Chandran, K, Charrel, R, Cheng, Q, Chiaki, Y, Chiapello, M, Choi, I, Ciuffo, M, Clegg, J, Crozier, I, Dal Bo, E, de la Torre, J, de Lamballerie, X, de Swart, R, Debat, H, Dheilly, N, Di Cicco, E, Di Paola, N, Di Serio, F, Dietzgen, R, Digiaro, M, Dolnik, O, Drebot, M, Drexler, J, Dundon, W, Duprex, W, Durrwald, R, Dye, J, Easton, A, Ebihara, H, Elbeaino, T, Ergunay, K, Ferguson, H, Fooks, A, Forgia, M, Formenty, P, Franova, J, Freitas-Astua, J, Fu, J, Furl, S, Gago-Zachert, S, Gao, G, Garcia, M, Garcia-Sastre, A, Garrison, A, Gaskin, T, Gonzalez, J, Griffiths, A, Goldberg, T, Groschup, M, Gunther, S, Hall, R, Hammond, J, Han, T, Hepojoki, J, Hewson, R, Hong, J, Hong, N, Hongo, S, Horie, M, Hu, J, Hu, T, Hughes, H, Huttner, F, Hyndman, T, Ilyas, M, Jalkanen, R, Jiang, D, Jonson, G, Junglen, S, Kadono, F, Kaukinen, K, Kawate, M, Klempa, B, Klingstrom, J, Kobinger, G, Koloniuk, I, Kondo, H, Koonin, E, Krupovic, M, Kubota, K, Kurath, G, Laenen, L, Lambert, A, Langevin, S, Lee, B, Lefkowitz, E, Leroy, E, Li, S, Li, L, Li, J, Liu, H, Lukashevich, I, Maes, P, de Souza, W, Marklewitz, M, Marshall, S, Marzano, S, Massart, S, Mccauley, J, Melzer, M, Mielke-Ehret, N, Miller, K, Ming, T, Mirazimi, A, Mordecai, G, Muhlbach, H, Muhlberger, E, Naidu, R, Natsuaki, T, Navarro, J, Netesov, S, Neumann, G, Nowotny, N, Nunes, M, Olmedo-Velarde, A, Palacios, G, Pallas, V, Palyi, B, Papa, A, Paraskevopoulou, S, Park, A, Parrish, C, Patterson, D, Pauvolid-Correa, A, Paweska, J, Payne, S, Peracchio, C, Perez, D, Postler, T, Qi, L, Radoshitzky, S, Resende, R, Reyes, C, Rima, B, Luna, G, Romanowski, V, Rota, P, Rubbenstroth, D, Rubino, L, Runstadler, J, Sabanadzovic, S, Sall, A, Salvato, M, Sang, R, Sasaya, T, Schulze, A, Schwemmle, M, Shi, M, Shi, X, Shi, Z, Shimomoto, Y, Shirako, Y, Siddell, S, Simmonds, P, Sironi, M, Smagghe, G, Smither, S, Song, J, Spann, K, Spengler, J, Stenglein, M, Stone, D, Sugano, J, Suttle, C, Tabata, A, Takada, A, Takeuchi, S, Tchouassi, D, Teffer, A, Tesh, R, Thornburg, N, Tomitaka, Y, Tomonaga, K, Tordo, N, Torto, B, Towner, J, Tsuda, S, Tu, C, Turina, M, Tzanetakis, I, Uchida, J, Usugi, T, Vaira, A, Vallino, M, van den Hoogen, B, Varsani, A, Vasilakis, N, Verbeek, M, von Bargen, S, Wada, J, Wahl, V, Walker, P, Wang, L, Wang, G, Wang, Y, Waqas, M, Wei, T, Wen, S, Whitfield, A, Williams, J, Wolf, Y, Wu, J, Xu, L, Yanagisawa, H, Yang, C, Yang, Z, Zerbini, F, Zhai, L, Zhang, Y, Zhang, S, Zhang, J, Zhang, Z, Zhou, X, Kuhn JH, Adkins S, Agwanda BR, Al Kubrusli R, Alkhovsky SV, Amarasinghe GK, Avsic-Zupanc T, Ayllon MA, Bahl J, Balkema-Buschmann A, Ballinger MJ, Basler CF, Bavari S, Beer M, Bejerman N, Bennett AJ, Bente DA, Bergeron E, Bird BH, Blair CD, Blasdell KR, Blystad DR, Bojko J, Borth WB, Bradfute S, Breyta R, Briese T, Brown PA, Brown JK, Buchholz UJ, Buchmeier MJ, Bukreyev A, Burt F, Buttner C, Calisher CH, Cao MJ, Casas I, Chandran K, Charrel RN, Cheng Q, Chiaki Y, Chiapello M, Choi I, Ciuffo M, Clegg JCS, Crozier I, Dal Bo E, de la Torre JC, de Lamballerie X, de Swart RL, Debat H, Dheilly NM, Di Cicco E, Di Paola N, Di Serio F, Dietzgen RG, Digiaro M, Dolnik O, Drebot MA, Drexler JF, Dundon WG, Duprex WP, Durrwald R, Dye JM, Easton AJ, Ebihara H, Elbeaino T, Ergunay K, Ferguson HW, Fooks AR, Forgia M, Formenty PBH, Franova J, Freitas-Astua J, Fu JJ, Furl S, Gago-Zachert S, Gao GF, Garcia ML, Garcia-Sastre A, Garrison AR, Gaskin T, Gonzalez JPJ, Griffiths A, Goldberg TL, Groschup MH, Gunther S, Hall RA, Hammond J, Han T, Hepojoki J, Hewson R, Hong J, Hong N, Hongo S, Horie M, Hu JS, Hu T, Hughes HR, Huttner F, Hyndman TH, Ilyas M, Jalkanen R, Jiang DH, Jonson GB, Junglen S, Kadono F, Kaukinen KH, Kawate M, Klempa B, Klingstrom J, Kobinger G, Koloniuk I, Kondo H, Koonin EV, Krupovic M, Kubota K, Kurath G, Laenen L, Lambert AJ, Langevin SL, Lee B, Lefkowitz EJ, Leroy EM, Li SR, Li LH, Li JR, Liu HZ, Lukashevich IS, Maes P, de Souza WM, Marklewitz M, Marshall SH, Marzano SYL, Massart S, McCauley JW, Melzer M, Mielke-Ehret N, Miller KM, Ming TJ, Mirazimi A, Mordecai GJ, Muhlbach HP, Muhlberger E, Naidu R, Natsuaki T, Navarro JA, Netesov SV, Neumann G, Nowotny N, Nunes MRT, Olmedo-Velarde A, Palacios G, Pallas V, Palyi B, Papa A, Paraskevopoulou S, Park AC, Parrish CR, Patterson DA, Pauvolid-Correa A, Paweska JT, Payne S, Peracchio C, Perez DR, Postler TS, Qi LY, Radoshitzky SR, Resende RO, Reyes CA, Rima BK, Luna GR, Romanowski V, Rota P, Rubbenstroth D, Rubino L, Runstadler JA, Sabanadzovic S, Sall AA, Salvato MS, Sang RS, Sasaya T, Schulze AD, Schwemmle M, Shi M, Shi XH, Shi ZL, Shimomoto Y, Shirako Y, Siddell SG, Simmonds P, Sironi M, Smagghe G, Smither S, Song JW, Spann K, Spengler JR, Stenglein MD, Stone DM, Sugano J, Suttle CA, Tabata A, Takada A, Takeuchi S, Tchouassi DP, Teffer A, Tesh RB, Thornburg NJ, Tomitaka Y, Tomonaga K, Tordo N, Torto B, Towner JS, Tsuda S, Tu CC, Turina M, Tzanetakis IE, Uchida J, Usugi T, Vaira AM, Vallino M, van den Hoogen B, Varsani A, Vasilakis N, Verbeek M, von Bargen S, Wada J, Wahl V, Walker PJ, Wang LF, Wang GP, Wang YX, Wang YQ, Waqas M, Wei TY, Wen SH, Whitfield AE, Williams JV, Wolf YI, Wu JX, Xu L, Yanagisawa H, Yang CX, Yang ZK, Zerbini FM, Zhai L, Zhang YZ, Zhang S, Zhang JG, Zhang Z, and Zhou XP

Abstract

In March 2021, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. The phylum was expanded by four families (Aliusviridae, Crepuscuviridae, Myriaviridae, and Natareviridae), three subfamilies (Alpharhabdovirinae, Betarhabdovirinae, and Gammarhabdovirinae), 42 genera, and 200 species. Thirty-nine species were renamed and/or moved and seven species were abolished. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV.

Published
2021

19. Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology

Author

Lin, FP, Thavaneswaran, S, Grady, JP, Ballinger, M, Kansara, M, Oakes, SR, Desai, J, Lee, CK, Simes, J, Thomas, DM, Lin, FP, Thavaneswaran, S, Grady, JP, Ballinger, M, Kansara, M, Oakes, SR, Desai, J, Lee, CK, Simes, J, and Thomas, DM

Abstract

While several resources exist that interpret therapeutic significance of genomic alterations in cancer, many regional real-world issues limit access to drugs. There is a need for a pragmatic, evidence-based, context-adapted tool to guide clinical management based on molecular biomarkers. To this end, we have structured a compendium of approved and experimental therapies with associated biomarkers following a survey of drug regulatory databases, existing knowledge bases, and published literature. Each biomarker-disease-therapy triplet was categorised using a tiering system reflective of key therapeutic considerations: approved and reimbursed therapies with respect to a jurisdiction (Tier 1), evidence of efficacy or approval in another jurisdiction (Tier 2), evidence of antitumour activity (Tier 3), and plausible biological rationale (Tier 4). Two resistance categories were defined: lack of efficacy (Tier R1) or antitumor activity (Tier R2). Based on this framework, we curated a digital resource focused on drugs relevant in the Australian healthcare system (TOPOGRAPH: Therapy Oriented Precision Oncology Guidelines for Recommending Anticancer Pharmaceuticals). As of November 2020, TOPOGRAPH comprised 2810 biomarker-disease-therapy triplets in 989 expert-appraised entries, including 373 therapies, 199 biomarkers, and 106 cancer types. In the 345 therapies catalogued, 84 (24%) and 65 (19%) were designated Tiers 1 and 2, respectively, while 271 (79%) therapies were supported by preclinical studies, early clinical trials, retrospective studies, or case series (Tiers 3 and 4). A companion algorithm was also developed to support rational, context-appropriate treatment selection informed by molecular biomarkers. This framework can be readily adapted to build similar resources in other jurisdictions to support therapeutic decision-making.

Published
2021

20. My Research Results supporting researchers to return clinically actionable genetic research findings.

Author

Willis A., Terrill B., Pearce A., McEwen A., Ballinger M., Milne R., Bruinsma F., Tiller J., Lacaze P., Young Ma.-A., Willis A., Terrill B., Pearce A., McEwen A., Ballinger M., Milne R., Bruinsma F., Tiller J., Lacaze P., and Young Ma.-A.

Abstract

Background: Australian researchers increasingly support returning clinically actionable genetic research findings to participants, but may lack the skills and resources to do so. Aim(s): Develop a program to support researchers and facilitate the return of clinically actionable research findings to participants. Method(s): The My Research Results (MyRR) program has been developed by a steering committee of clinicians, researchers, genetic educators and consumers. MyRR supports researchers to return clinically actionable research findings to participants. MyRRis staffed by genetic counsellors and available to researchers Australia-wide. Participants are notified of findings by letter, with a follow-up phone call from a genetic counsellor. The MyRR experience of returning findings from the Melbourne Collaborative Cohort Study and the ASPREE Study is reported. Result(s): Twenty-three individuals across the two studies were notified of clinically actionable findings from February to May 2021. Notification letters were sent to probands (n = 21) or, if deceased, the nominated next-of-kin (n = 2). MyRR genetic counsellors successfully contacted 21 individuals (12 women and nine men) regarding pathogenic variants in BRCA1 (n = 6), BRCA2 (n = 13), MSH6 (n = 1) and PMS2 (n = 1). The average age of notified probands was 81 years. Findings were disclosed to 20 individuals, one declined to receive the findings. Thirteen probands expressed an intention to attend a clinical genetics service for confirmatory testing and risk management advice. Five individuals were already aware of the findings. Conclusion(s): MyRR is a translational program promoting and facilitating access to clinically actionable genetic research findings, filling an important gap for Australian research studies and delivering health benefits to research participants.

Published
2021

21. The experiences and needs of australian medical oncologists in integrating comprehensive genomic profiling into clinical care: A nation-wide survey

Author

Thavaneswaran, S, Ballinger, M, Butow, P, Meiser, B, Goldstein, D, Lin, F, Napier, C, Thomas, D, Best, M, Thavaneswaran, S, Ballinger, M, Butow, P, Meiser, B, Goldstein, D, Lin, F, Napier, C, Thomas, D, and Best, M

Abstract

Purpose: Comprehensive genomic profiling (CGP) is increasingly used to guide cancer therapy. This study aimed to characterise oncologists' experiences and needs when utilising genomic results. Materials and Methods: An electronic survey distributed nation-wide to practising medical oncologists in Australia explored oncologists' experiences with consenting, interpreting and communicating CGP results to patients. Results: The survey was completed by 108 of 333 oncologists (32%) and most respondents (n = 97, 90%) had referred patients for CGP. Using a 100-point visual analogue scale score [VAS], where higher values indicate greater confidence, most oncologists were confident consenting patients for referral [median 75 (Interquartile range, IQR: 53-85), discussing CGP results (median VAS: 70, IQR: 51-80), but significantly less confident discussing secondary germline findings (median VAS: 56, IQR 30-70, p < 0.001). Confidence with pursuing therapies based on CGP results increased with clinical experience (mean VAS increases by 4.8 per 5 years of experience, p < 0.001). Most oncologists (N = 68, 63%) reported wanting assistance with interpretation of CGP and patient-centric resources to aid communication with patients. Conclusions: Oncologists are integrating genomics into clinical care, but only display moderate confidence in communication and changing management accordingly. The development of patient- and clinician- targeted resources may assist with routine utilisation of CGP results in cancer care.

Published
2021

22. 1264MO IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)

Author

Altorki, N.K., Reck, M., Wakelee, H., Felip, E., Vallieres, E., Liersch, R., Oizumi, S., Tanaka, H., Novello, S., McCune, S., Li, H., Molinero, L., Müller, S., Bennett, E., Gitlitz, B.J., McNally, V.A., Ballinger, M., Nabet, B., Srivastava, M.K., and Zhou, C.

Published
2023
Full Text
View/download PDF

23. P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

Author

Patil, N., primary, Cho, B.C., additional, Johnson, M., additional, Caro, R.B., additional, Spira, A., additional, Chiu, C., additional, Molden, N., additional, Pham, T., additional, Yang, X., additional, Choi, Y., additional, Zhang, Z., additional, Hoang, T., additional, Ballinger, M., additional, Meng, R., additional, and Rodríguez-Abreu, D., additional

Published
2021
Full Text
View/download PDF

24. Patient-Reported Outcomes in OAK: A Phase III Study of Atezolizumab Versus Docetaxel in Advanced Non-Small-cell Lung Cancer

Author

Bordoni, R, Ciardiello, F, von Pawel, J, Cortinovis, D, Karagiannis, T, Ballinger, M, Sandler, A, Yu, W, He, P, Matheny, C, Felizzi, F, Rittmeyer, A, Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, Rittmeyer A., Bordoni, R, Ciardiello, F, von Pawel, J, Cortinovis, D, Karagiannis, T, Ballinger, M, Sandler, A, Yu, W, He, P, Matheny, C, Felizzi, F, Rittmeyer, A, Bordoni R, Ciardiello F, von Pawel J, Cortinovis D, Karagiannis T, Ballinger M, Sandler A, Yu W, He P, Matheny C, Felizzi F, and Rittmeyer A.

Abstract

OAK, a phase III advanced non–small-cell lung cancer (NSCLC) trial, compared the investigational drug atezolizumab with the standard chemotherapy agent docetaxel. The patient-reported outcomes data revealed that atezolizumab prolonged the time to the worsening of disease-related symptoms, such as chest pain, and maintained patients’ health-related quality of life. These data further support the use of atezolizumab in the treatment of advanced NSCLC. Background: The randomized phase III OAK (a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non–small-cell lung cancer [NSCLC] who have failed platinum-containing therapy) trial investigated the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab for advanced or metastatic, previously treated, NSCLC. Atezolizumab significantly improved overall survival (OS) compared with docetaxel (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.62-0.87; P =.0003; median OS, 13.8 vs. 9.6 months, respectively). Patient-reported outcomes (PROs) were collected to evaluate disease-related symptoms and health-related quality of life (HRQoL) to support the finding of a survival benefit. Patients and Methods: The first 850 patients were randomized to receive atezolizumab (1200 mg every 3 weeks) or docetaxel (75 mg/m 2 every 3 weeks). PROs were collected on day 1 of cycle 1, day 1 of every subsequent cycle, and at the end-of-treatment visit for patients who completed ≥ 1 baseline and 1 postbaseline PRO assessment. The European Organisation for the Research and Treatment of Cancer QoL questionnaire and lung cancer module were used to assess PROs. Results: Atezolizumab delayed the time to deterioration (TTD) in physical function (HR, 0.75; 95% CI, 0.58-0.98) and role function (HR, 0.79; 95% CI, 0.62-1.00) and numerically improved patients’ HRQoL from baseline compared with docetaxel. Atezolizumab also prolonged the TTD in chest pain (HR, 0.71; 95% CI, 0.49-1.05; P =.0823), al

Published
2018

25. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Author

Fehrenbacher, L, von Pawel, J, Park, K, Rittmeyer, A, Gandara, D, Ponce Aix, S, Han, J, Gadgeel, S, Hida, T, Cortinovis, D, Cobo, M, Kowalski, D, De Marinis, F, Gandhi, M, Danner, B, Matheny, C, Kowanetz, M, He, P, Felizzi, F, Patel, H, Sandler, A, Ballinger, M, Barlesi, F, Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis D, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F., Fehrenbacher, L, von Pawel, J, Park, K, Rittmeyer, A, Gandara, D, Ponce Aix, S, Han, J, Gadgeel, S, Hida, T, Cortinovis, D, Cobo, M, Kowalski, D, De Marinis, F, Gandhi, M, Danner, B, Matheny, C, Kowanetz, M, He, P, Felizzi, F, Patel, H, Sandler, A, Ballinger, M, Barlesi, F, Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis D, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, and Barlesi F.

Abstract

Introduction: The efficacy and safety of atezolizumab versus the efficacy and safety of docetaxel as second- or third-line treatment in patients with advanced NSCLC in the primary (n = 850) and secondary (n = 1225) efficacy populations of the randomized phase III OAK study (respectively referred to as the intention-to-treat [ITT] 850 [ITT850] and ITT1225) at an updated data cutoff were assessed. Methods: Patients received atezolizumab, 1200 mg, or docetaxel, 75 mg/m2, intravenously every 3 weeks until loss of clinical benefit or disease progression, respectively. The primary end point was overall survival (OS) in the ITT population and programmed death-ligand 1–expressing subgroup. A sensitivity analysis was conducted to evaluate the impact of subsequent immunotherapy use in the docetaxel arm on the observed survival benefit with atezolizumab. Results: Atezolizumab demonstrated an OS benefit versus docetaxel in the updated ITT850 (hazard ratio [HR] = 0.75, 95% confidence interval: 0.64–0.89, p = 0.0006) and the ITT1225 (HR = 0.80, 95% confidence interval: 0.70–0.92, p = 0.0012) after minimum follow-up times of 26 and 21 months, respectively. Improved survival with atezolizumab was observed across programmed death-ligand 1 and histological subgroups. In the immunotherapy sensitivity analysis, the relative OS benefit with atezolizumab was slightly greater in the ITT850 (HR = 0.69) and ITT1225 (HR = 0.74) than the conventional OS estimate. Fewer patients receiving atezolizumab experienced grade 3 or 4 treatment-related adverse events (14.9%) than did patients receiving docetaxel (42.4%); no grade 5 adverse events related to atezolizumab were observed. Conclusions: The results of the updated ITT850 and initial ITT1225 analyses were consistent with those of the primary efficacy analysis demonstrating survival benefit with atezolizumab versus with docetaxel. Atezolizumab continued to demonstrate a favorable safety profile after longer treatment exposure and follow-up.

Published
2018

27. 2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales

Author

Kuhn, J, Adkins, S, Alioto, D, Alkhovsky, S, Amarasinghe, G, Anthony, S, Avsic-Aupanc, T, Ayllon, M, Bahl, J, Balkema-Buschmann, A, Ballinger, M, Bartonicka, T, Basler, C, Bavari, S, Beer, M, Bente, D, Bergeron, E, Bird, B, Blair, C, Blasdell, K, Bradfute, S, Breyta, R, Briese, T, Brown, P, Buchholz, U, Buchmeier, M, Bukreyev, A, Burt, F, Buzkan, N, Calisher, C, Cao, M, Casas, I, Chamberlain, J, Chandran, K, Charrel, R, Chen, B, Chiumenti, M, Choi, I, Clegg, J, Crozier, I, da Graca, J, Dal Bo, E, Davila, A, de la Torre, J, de Lamballerie, X, de Swart, R, Di Bello, P, Di Paola, N, Di Serio, F, Dietzgen, R, Digiaro, M, Dolja, V, Dolnik, O, Drebot, M, Drexler, J, Durrwald, R, Dufkova, L, Dundon, W, Duprex, W, Dye, J, Easton, A, Ebihara, H, Elbeaino, T, Ergunay, K, Fernandes, J, Fooks, A, Formenty, P, Forth, L, Fouchier, R, Freitas-Astua, J, Gago-Zachert, S, Gao, G, Garcia, M, Garcia-Sastre, A, Garrison, A, Gbakima, A, Goldstein, T, Gonzalez, J, Griffiths, A, Groschup, M, Gunther, S, Guterres, A, Hall, R, Hammond, J, Hassan, M, Hepojoki, J, Hepojoki, S, Hetzel, U, Hewson, R, Hoffmann, B, Hongo, S, Hoper, D, Horie, M, Hughes, H, Hyndman, T, Jambai, A, Jardim, R, Jiang, D, Jin, Q, Jonson, G, Junglen, S, Karadag, S, Keller, K, Klempa, B, Klingstrom, J, Kobinger, G, Kondo, H, Koonin, E, Krupovic, M, Kurath, G, Kuzmin, I, Laenen, L, Lamb, R, Lambert, A, Langevin, S, Lee, B, Lemos, E, Leroy, E, Li, D, Li, J, Liang, M, Liu, W, Liu, Y, Lukashevich, I, Maes, P, de Souza, W, Marklewitz, M, Marshall, S, Martelli, G, Martin, R, Marzano, S, Massart, S, Mccauley, J, Mielke-Ehret, N, Minafra, A, Minutolo, M, Mirazimi, A, Muhlbach, H, Muhlberger, E, Naidu, R, Natsuaki, T, Navarro, B, Navarro, J, Netesov, S, Neumann, G, Nowotny, N, Nunes, M, Nylund, A, Okland, A, Oliveira, R, Palacios, G, Pallas, V, Palyi, B, Papa, A, Parrish, C, Pauvolid-Correa, A, Paweska, J, Payne, S, Perez, D, Pfaff, F, Radoshitzky, S, Aziz-ul, R, Ramos-Gonzalez, P, Resende, R, Reyes, C, Rima, B, Romanowski, V, Luna, G, Rota, P, Rubbenstroth, D, Runstadler, J, Ruzek, D, Sabanadzovic, S, Salat, J, Sall, A, Salvato, M, Sarpkaya, K, Sasaya, T, Schwemmle, M, Shabbir, M, Shi, X, Shi, Z, Shirako, Y, Simmonds, P, Sirmarovaa, J, Sironi, M, Smither, S, Smura, T, Song, J, Spann, K, Spengler, J, Stenglein, M, Stone, D, Strakova, P, Takada, A, Tesh, R, Thornburg, N, Tomonaga, K, Tordo, N, Towner, J, Turina, M, Tzanetakis, I, Ulrich, R, Vaira, A, van den Hoogen, B, Varsani, A, Vasilakis, N, Verbeek, M, Wahl, V, Walker, P, Wang, H, Wang, J, Wang, X, Wang, L, Wei, T, Wells, H, Whitfield, A, Williams, J, Wolf, Y, Wu, Z, Yang, X, Yu, X, Yutin, N, Zerbini, F, Zhang, T, Zhang, Y, Zhou, G, Zhou, X, Kuhn JH, Adkins S, Alioto D, Alkhovsky SV, Amarasinghe GK, Anthony SJ, Avsic-Aupanc T, Ayllon MA, Bahl J, Balkema-Buschmann A, Ballinger MJ, Bartonicka T, Basler C, Bavari S, Beer M, Bente DA, Bergeron E, Bird BH, Blair C, Blasdell KR, Bradfute SB, Breyta R, Briese T, Brown PA, Buchholz UJ, Buchmeier MJ, Bukreyev A, Burt F, Buzkan N, Calisher CH, Cao MJ, Casas I, Chamberlain J, Chandran K, Charrel RN, Chen B, Chiumenti M, Choi I, Clegg JCS, Crozier I, da Graca JV, Dal Bo E, Davila AMR, de la Torre JC, de Lamballerie X, de Swart RL, Di Bello PL, Di Paola N, Di Serio F, Dietzgen RG, Digiaro M, Dolja VV, Dolnik O, Drebot MA, Drexler JF, Durrwald R, Dufkova L, Dundon WG, Duprex WP, Dye JM, Easton AJ, Ebihara H, Elbeaino T, Ergunay K, Fernandes J, Fooks AR, Formenty PBH, Forth LF, Fouchier RAM, Freitas-Astua J, Gago-Zachert S, Gao GF, Garcia ML, Garcia-Sastre A, Garrison AR, Gbakima A, Goldstein T, Gonzalez JPJ, Griffiths A, Groschup MH, Gunther S, Guterres A, Hall RA, Hammond J, Hassan M, Hepojoki J, Hepojoki S, Hetzel U, Hewson R, Hoffmann B, Hongo S, Hoper D, Horie M, Hughes HR, Hyndman TH, Jambai A, Jardim R, Jiang DH, Jin Q, Jonson GB, Junglen S, Karadag S, Keller KE, Klempa B, Klingstrom J, Kobinger G, Kondo H, Koonin EV, Krupovic M, Kurath G, Kuzmin IV, Laenen L, Lamb RA, Lambert AJ, Langevin SL, Lee BH, Lemos ERS, Leroy EM, Li DX, Li JR, Liang MF, Liu WW, Liu Y, Lukashevich IS, Maes P, de Souza WM, Marklewitz M, Marshall SH, Martelli GP, Martin RR, Marzano SYL, Massart S, McCauley JW, Mielke-Ehret N, Minafra A, Minutolo M, Mirazimi A, Muhlbach HP, Muhlberger E, Naidu R, Natsuaki T, Navarro B, Navarro JA, Netesov SV, Neumann G, Nowotny N, Nunes MRT, Nylund A, Okland AL, Oliveira RC, Palacios G, Pallas V, Palyi B, Papa A, Parrish CR, Pauvolid-Correa A, Paweska JT, Payne S, Perez DR, Pfaff F, Radoshitzky SR, Aziz-ul Rahman, Ramos-Gonzalez PL, Resende RO, Reyes CA, Rima BK, Romanowski V, Luna GR, Rota P, Rubbenstroth D, Runstadler JA, Ruzek D, Sabanadzovic S, Salat J, Sall AA, Salvato MS, Sarpkaya K, Sasaya T, Schwemmle M, Shabbir MZ, Shi XH, Shi ZL, Shirako Y, Simmonds P, Sirmarovaa J, Sironi M, Smither S, Smura T, Song JW, Spann KM, Spengler JR, Stenglein MD, Stone DM, Strakova P, Takada A, Tesh RB, Thornburg NJ, Tomonaga K, Tordo N, Towner JS, Turina M, Tzanetakis I, Ulrich RG, Vaira AM, van den Hoogen B, Varsani A, Vasilakis N, Verbeek M, Wahl V, Walker PJ, Wang H, Wang JW, Wang XF, Wang LF, Wei TY, Wells H, Whitfield AE, Williams JV, Wolf YI, Wu ZQ, Yang X, Yu XJ, Yutin N, Zerbini FM, Zhang T, Zhang YZ, Zhou GH, Zhou XP, Kuhn, J, Adkins, S, Alioto, D, Alkhovsky, S, Amarasinghe, G, Anthony, S, Avsic-Aupanc, T, Ayllon, M, Bahl, J, Balkema-Buschmann, A, Ballinger, M, Bartonicka, T, Basler, C, Bavari, S, Beer, M, Bente, D, Bergeron, E, Bird, B, Blair, C, Blasdell, K, Bradfute, S, Breyta, R, Briese, T, Brown, P, Buchholz, U, Buchmeier, M, Bukreyev, A, Burt, F, Buzkan, N, Calisher, C, Cao, M, Casas, I, Chamberlain, J, Chandran, K, Charrel, R, Chen, B, Chiumenti, M, Choi, I, Clegg, J, Crozier, I, da Graca, J, Dal Bo, E, Davila, A, de la Torre, J, de Lamballerie, X, de Swart, R, Di Bello, P, Di Paola, N, Di Serio, F, Dietzgen, R, Digiaro, M, Dolja, V, Dolnik, O, Drebot, M, Drexler, J, Durrwald, R, Dufkova, L, Dundon, W, Duprex, W, Dye, J, Easton, A, Ebihara, H, Elbeaino, T, Ergunay, K, Fernandes, J, Fooks, A, Formenty, P, Forth, L, Fouchier, R, Freitas-Astua, J, Gago-Zachert, S, Gao, G, Garcia, M, Garcia-Sastre, A, Garrison, A, Gbakima, A, Goldstein, T, Gonzalez, J, Griffiths, A, Groschup, M, Gunther, S, Guterres, A, Hall, R, Hammond, J, Hassan, M, Hepojoki, J, Hepojoki, S, Hetzel, U, Hewson, R, Hoffmann, B, Hongo, S, Hoper, D, Horie, M, Hughes, H, Hyndman, T, Jambai, A, Jardim, R, Jiang, D, Jin, Q, Jonson, G, Junglen, S, Karadag, S, Keller, K, Klempa, B, Klingstrom, J, Kobinger, G, Kondo, H, Koonin, E, Krupovic, M, Kurath, G, Kuzmin, I, Laenen, L, Lamb, R, Lambert, A, Langevin, S, Lee, B, Lemos, E, Leroy, E, Li, D, Li, J, Liang, M, Liu, W, Liu, Y, Lukashevich, I, Maes, P, de Souza, W, Marklewitz, M, Marshall, S, Martelli, G, Martin, R, Marzano, S, Massart, S, Mccauley, J, Mielke-Ehret, N, Minafra, A, Minutolo, M, Mirazimi, A, Muhlbach, H, Muhlberger, E, Naidu, R, Natsuaki, T, Navarro, B, Navarro, J, Netesov, S, Neumann, G, Nowotny, N, Nunes, M, Nylund, A, Okland, A, Oliveira, R, Palacios, G, Pallas, V, Palyi, B, Papa, A, Parrish, C, Pauvolid-Correa, A, Paweska, J, Payne, S, Perez, D, Pfaff, F, Radoshitzky, S, Aziz-ul, R, Ramos-Gonzalez, P, Resende, R, Reyes, C, Rima, B, Romanowski, V, Luna, G, Rota, P, Rubbenstroth, D, Runstadler, J, Ruzek, D, Sabanadzovic, S, Salat, J, Sall, A, Salvato, M, Sarpkaya, K, Sasaya, T, Schwemmle, M, Shabbir, M, Shi, X, Shi, Z, Shirako, Y, Simmonds, P, Sirmarovaa, J, Sironi, M, Smither, S, Smura, T, Song, J, Spann, K, Spengler, J, Stenglein, M, Stone, D, Strakova, P, Takada, A, Tesh, R, Thornburg, N, Tomonaga, K, Tordo, N, Towner, J, Turina, M, Tzanetakis, I, Ulrich, R, Vaira, A, van den Hoogen, B, Varsani, A, Vasilakis, N, Verbeek, M, Wahl, V, Walker, P, Wang, H, Wang, J, Wang, X, Wang, L, Wei, T, Wells, H, Whitfield, A, Williams, J, Wolf, Y, Wu, Z, Yang, X, Yu, X, Yutin, N, Zerbini, F, Zhang, T, Zhang, Y, Zhou, G, Zhou, X, Kuhn JH, Adkins S, Alioto D, Alkhovsky SV, Amarasinghe GK, Anthony SJ, Avsic-Aupanc T, Ayllon MA, Bahl J, Balkema-Buschmann A, Ballinger MJ, Bartonicka T, Basler C, Bavari S, Beer M, Bente DA, Bergeron E, Bird BH, Blair C, Blasdell KR, Bradfute SB, Breyta R, Briese T, Brown PA, Buchholz UJ, Buchmeier MJ, Bukreyev A, Burt F, Buzkan N, Calisher CH, Cao MJ, Casas I, Chamberlain J, Chandran K, Charrel RN, Chen B, Chiumenti M, Choi I, Clegg JCS, Crozier I, da Graca JV, Dal Bo E, Davila AMR, de la Torre JC, de Lamballerie X, de Swart RL, Di Bello PL, Di Paola N, Di Serio F, Dietzgen RG, Digiaro M, Dolja VV, Dolnik O, Drebot MA, Drexler JF, Durrwald R, Dufkova L, Dundon WG, Duprex WP, Dye JM, Easton AJ, Ebihara H, Elbeaino T, Ergunay K, Fernandes J, Fooks AR, Formenty PBH, Forth LF, Fouchier RAM, Freitas-Astua J, Gago-Zachert S, Gao GF, Garcia ML, Garcia-Sastre A, Garrison AR, Gbakima A, Goldstein T, Gonzalez JPJ, Griffiths A, Groschup MH, Gunther S, Guterres A, Hall RA, Hammond J, Hassan M, Hepojoki J, Hepojoki S, Hetzel U, Hewson R, Hoffmann B, Hongo S, Hoper D, Horie M, Hughes HR, Hyndman TH, Jambai A, Jardim R, Jiang DH, Jin Q, Jonson GB, Junglen S, Karadag S, Keller KE, Klempa B, Klingstrom J, Kobinger G, Kondo H, Koonin EV, Krupovic M, Kurath G, Kuzmin IV, Laenen L, Lamb RA, Lambert AJ, Langevin SL, Lee BH, Lemos ERS, Leroy EM, Li DX, Li JR, Liang MF, Liu WW, Liu Y, Lukashevich IS, Maes P, de Souza WM, Marklewitz M, Marshall SH, Martelli GP, Martin RR, Marzano SYL, Massart S, McCauley JW, Mielke-Ehret N, Minafra A, Minutolo M, Mirazimi A, Muhlbach HP, Muhlberger E, Naidu R, Natsuaki T, Navarro B, Navarro JA, Netesov SV, Neumann G, Nowotny N, Nunes MRT, Nylund A, Okland AL, Oliveira RC, Palacios G, Pallas V, Palyi B, Papa A, Parrish CR, Pauvolid-Correa A, Paweska JT, Payne S, Perez DR, Pfaff F, Radoshitzky SR, Aziz-ul Rahman, Ramos-Gonzalez PL, Resende RO, Reyes CA, Rima BK, Romanowski V, Luna GR, Rota P, Rubbenstroth D, Runstadler JA, Ruzek D, Sabanadzovic S, Salat J, Sall AA, Salvato MS, Sarpkaya K, Sasaya T, Schwemmle M, Shabbir MZ, Shi XH, Shi ZL, Shirako Y, Simmonds P, Sirmarovaa J, Sironi M, Smither S, Smura T, Song JW, Spann KM, Spengler JR, Stenglein MD, Stone DM, Strakova P, Takada A, Tesh RB, Thornburg NJ, Tomonaga K, Tordo N, Towner JS, Turina M, Tzanetakis I, Ulrich RG, Vaira AM, van den Hoogen B, Varsani A, Vasilakis N, Verbeek M, Wahl V, Walker PJ, Wang H, Wang JW, Wang XF, Wang LF, Wei TY, Wells H, Whitfield AE, Williams JV, Wolf YI, Wu ZQ, Yang X, Yu XJ, Yutin N, Zerbini FM, Zhang T, Zhang YZ, Zhou GH, and Zhou XP

Abstract

In March 2020, following the annual International Committee on Taxonomy of Viruses (ICTV) ratification vote on newly proposed taxa, the phylum Negarnaviricota was amended and emended. At the genus rank, 20 new genera were added, two were deleted, one was moved, and three were renamed. At the species rank, 160 species were added, four were deleted, ten were moved and renamed, and 30 species were renamed. This article presents the updated taxonomy of Negarnaviricota as now accepted by the ICTV.

Published
2020

33. IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)

Author

Reck, M, additional, Jotte, R, additional, Cappuzzo, F, additional, Mok, T, additional, West, H, additional, Nishio, M, additional, Papadimitrakopoulou, VA, additional, Orlandi, F, additional, Stroyakovskii, D, additional, Thomas, C, additional, Nogami, N, additional, Barlesi, F, additional, Lee, A, additional, Shankar, G, additional, Yu, W, additional, Ballinger, M, additional, Bara, I, additional, Sandler, A, additional, and Socinski, M, additional

Published
2020
Full Text
View/download PDF

34. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Author

Rittmeyer, A, Barlesi, F, Waterkamp, D, Park, K, Ciardiello, F, von Pawel, J, Gadgeel, S, Hida, T, Kowalski, D, Dols, M, Cortinovis, D, Leach, J, Polikoff, J, Barrios, C, Kabbinavar, F, Frontera, O, De Marinis, F, Turna, H, Lee, J, Ballinger, M, Kowanetz, M, He, P, Chen, D, Sandler, A, Gandara, D, Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis D, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, Gandara DR, Rittmeyer, A, Barlesi, F, Waterkamp, D, Park, K, Ciardiello, F, von Pawel, J, Gadgeel, S, Hida, T, Kowalski, D, Dols, M, Cortinovis, D, Leach, J, Polikoff, J, Barrios, C, Kabbinavar, F, Frontera, O, De Marinis, F, Turna, H, Lee, J, Ballinger, M, Kowanetz, M, He, P, Chen, D, Sandler, A, Gandara, D, Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols MC, Cortinovis D, Leach J, Polikoff J, Barrios C, Kabbinavar F, Frontera OA, De Marinis F, Turna H, Lee JS, Ballinger M, Kowanetz M, He P, Chen DS, Sandler A, and Gandara DR

Abstract

Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer. Methods We did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries. We enrolled patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer. Patients with a history of autoimmune disease and those who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway were excluded. Patients were randomly assigned (1:1) to intravenously receive either atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 weeks by permuted block randomisation (block size of eight) via an interactive voice or web response system. Coprimary endpoints were overall survival in the intention-to-treat (ITT) and PD-L1-expression population TC1/2/3 or IC1/2/3 (≥1% PD-L1 on tumour cells or tumour-infiltrating immune cells). The primary efficacy analysis was done in the first 850 of 1225 enrolled patients. This study is registered with ClinicalTrials.gov, number NCT02008227. Findings Between March 11, 2014, and April 29, 2015, 1225 patients were recruited. In the primary population, 425 patients were randomly assigned to receive atezolizumab and 425 patients were assigned to receive docetaxel. Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations. In the ITT

Published
2017

35. Pacific Northwest National Laboratory Annual Site Environmental Report for Calendar Year 2014

Author

Duncan, J. P., primary, Sackschewsky, M. R., additional, Tilden, H. T., additional, Su-Coker, J., additional, Mendez, J. L., additional, Ballinger, M. Y., additional, Fritz, B. G., additional, Stoetzel, G. A., additional, Barnett, J. M., additional, Lowry, K. L., additional, Moon, T. W., additional, Becker, J. M., additional, and Chamness, M. A., additional

Published
2015
Full Text
View/download PDF

37. Patient perspectives on molecular tumor profiling: 'why wouldn't you?'

Author

Best, MC, Bartley, N, Jacobs, C, Juraskova, I, Goldstein, D, Newson, AJ, Savard, J, Meiser, B, Ballinger, M, Napier, C, Thomas, D, Biesecker, B, Butow, P, Tucker, K, Schlub, T, Vines, R, Vines, K, Kirk, J, and Young, MA

Subjects
Adult, Male, Health Knowledge, Attitudes, Practice, Patients, Middle Aged, Survival Analysis, Cohort Studies, Patient Education as Topic, Neoplasms, Humans, Female, Oncology & Carcinogenesis, Patient Participation, Pathology, Molecular, Neoplasm Staging, Aged
Abstract

© 2019 The Author(s). Aim: This study explored the attitudes of patients with advanced cancer towards MTP and return of results, prior to undergoing genomic testing within a research program. Methods: Participants were recruited as part of the longitudinal PiGeOn (Psychosocial Issues in Genomics in Oncology) study involving patients with advanced/metastatic solid cancer who had exhausted therapeutic options and who were offered MTP in order to identify cognate therapies. Twenty patients, selected by purposive sampling, were interviewed around the time they gave consent to MTP. Interviews were audio recorded, transcribed and analysed using thematic analysis. Themes identified in the transcripts were cross-validated via qualitative responses to the PiGeOn study survey (n = 569; 63%). Results: All interviewed participants gave consent to MTP without reservation. Three themes were identified and further supported via the survey responses: (1) Obvious agreement to participate, primarily because of desire for new treatments and altruism. (2) The black box - while participant knowledge of genomics was generally poor, faith in their oncologists and the scientific process encouraged them to proceed with testing; and (3) Survival is the priority - receiving treatment to prolong life was the priority for all participants, and other issues such as identification of a germline variant were generally seen as ancillary. Conclusion: Having advanced cancer seemed to abrogate any potential concerns about MTP. Participants valued the research for varied reasons, but this was secondary to their priority to survive. While no negative attitudes toward MTP emerged, limitations in understanding of genomics were evident.

Published
2019

38. Taxonomy of the order Bunyavirales: update 2019

Author

Abudurexiti, A, Adkins, S, Alioto, D, Alkhovsky, S, Avsic-Zupanc, T, Ballinger, M, Bente, D, Beer, M, Bergeron, E, Blair, C, Briese, T, Buchmeier, M, Burt, F, Calisher, C, Chang, C, Charrel, R, Choi, I, Clegg, J, la Torre, J, Lamballerie, X, Deng, F, Di Serio, F, Digiaro, M, Drebot, M, Duan, X, Ebihara, H, Elbeaino, T, Ergunay, K, Fulhorst, C, Garrison, A, Gao, G, Gonzalez, J, Groschup, M, Guenther, S, Haenni, A, Hall, R, Hepojoki, J, Hewson, R, Hu, Z, Hughes, H, Jonson, M, Junglen, S, Klempa, B, Klingstrom, J, Kou, C, Laenen, L, Lambert, A, Langevin, S, Liu, D, Lukashevich, I, Luo, T, Lu, C, Maes, P, de Souza, W, Marklewitz, M, Martelli, G, Matsuno, K, Mielke-Ehret, N, Minutolo, M, Mirazimi, A, Moming, A, Muhlbach, H, Naidu, R, Navarro, B, Nunes, M, Palacios, G, Papa, A, Pauvolid-Correa, A, Paweska, J, Qiao, J, Radoshitzky, S, Resende, R, Romanowski, V, Sall, A, Salvato, M, Sasaya, T, Shen, S, Shi, X, Shirako, Y, Simmonds, P, Sironi, M, Song, J, Spengler, J, Stenglein, M, Su, Z, Sun, S, Tang, S, Turina, M, Wang, B, Wang, C, Wang, H, Wang, J, Wei, T, Whitfield, A, Zerbini, F, Zhang, J, Zhang, L, Zhang, Y, Zhou, X, Zhu, L, Kuhn, J, Abudurexiti A, Adkins S, Alioto D, Alkhovsky SV, Avsic-Zupanc T, Ballinger MJ, Bente DA, Beer M, Bergeron E, Blair CD, Briese T, Buchmeier MJ, Burt FJ, Calisher CH, Chang C, Charrel RN, Choi IR, Clegg JCS, la Torre JC, Lamballerie X, Deng F, Di Serio F, Digiaro M, Drebot MA, Duan XM, Ebihara H, Elbeaino T, Ergunay K, Fulhorst CF, Garrison AR, Gao GF, Gonzalez JPJ, Groschup MH, Guenther S, Haenni AL, Hall RA, Hepojoki J, Hewson R, Hu Z, Hughes HR, Jonson MG, Junglen S, Klempa B, Klingstrom J, Kou C, Laenen L, Lambert AJ, Langevin SA, Liu D, Lukashevich IS, Luo T, Lu CW, Maes P, de Souza WM, Marklewitz M, Martelli GP, Matsuno K, Mielke-Ehret N, Minutolo M, Mirazimi A, Moming A, Muhlbach HP, Naidu R, Navarro B, Nunes MRT, Palacios G, Papa A, Pauvolid-Correa A, Paweska JT, Qiao J, Radoshitzky SR, Resende RO, Romanowski V, Sall AA, Salvato MS, Sasaya T, Shen S, Shi XH, Shirako Y, Simmonds P, Sironi M, Song JW, Spengler JR, Stenglein MD, Su ZY, Sun S, Tang S, Turina M, Wang B, Wang C, Wang HL, Wang J, Wei TY, Whitfield AE, Zerbini FM, Zhang J, Zhang L, Zhang YF, Zhang YZ, Zhang Y, Zhou X, Zhu L, Kuhn JH, Abudurexiti, A, Adkins, S, Alioto, D, Alkhovsky, S, Avsic-Zupanc, T, Ballinger, M, Bente, D, Beer, M, Bergeron, E, Blair, C, Briese, T, Buchmeier, M, Burt, F, Calisher, C, Chang, C, Charrel, R, Choi, I, Clegg, J, la Torre, J, Lamballerie, X, Deng, F, Di Serio, F, Digiaro, M, Drebot, M, Duan, X, Ebihara, H, Elbeaino, T, Ergunay, K, Fulhorst, C, Garrison, A, Gao, G, Gonzalez, J, Groschup, M, Guenther, S, Haenni, A, Hall, R, Hepojoki, J, Hewson, R, Hu, Z, Hughes, H, Jonson, M, Junglen, S, Klempa, B, Klingstrom, J, Kou, C, Laenen, L, Lambert, A, Langevin, S, Liu, D, Lukashevich, I, Luo, T, Lu, C, Maes, P, de Souza, W, Marklewitz, M, Martelli, G, Matsuno, K, Mielke-Ehret, N, Minutolo, M, Mirazimi, A, Moming, A, Muhlbach, H, Naidu, R, Navarro, B, Nunes, M, Palacios, G, Papa, A, Pauvolid-Correa, A, Paweska, J, Qiao, J, Radoshitzky, S, Resende, R, Romanowski, V, Sall, A, Salvato, M, Sasaya, T, Shen, S, Shi, X, Shirako, Y, Simmonds, P, Sironi, M, Song, J, Spengler, J, Stenglein, M, Su, Z, Sun, S, Tang, S, Turina, M, Wang, B, Wang, C, Wang, H, Wang, J, Wei, T, Whitfield, A, Zerbini, F, Zhang, J, Zhang, L, Zhang, Y, Zhou, X, Zhu, L, Kuhn, J, Abudurexiti A, Adkins S, Alioto D, Alkhovsky SV, Avsic-Zupanc T, Ballinger MJ, Bente DA, Beer M, Bergeron E, Blair CD, Briese T, Buchmeier MJ, Burt FJ, Calisher CH, Chang C, Charrel RN, Choi IR, Clegg JCS, la Torre JC, Lamballerie X, Deng F, Di Serio F, Digiaro M, Drebot MA, Duan XM, Ebihara H, Elbeaino T, Ergunay K, Fulhorst CF, Garrison AR, Gao GF, Gonzalez JPJ, Groschup MH, Guenther S, Haenni AL, Hall RA, Hepojoki J, Hewson R, Hu Z, Hughes HR, Jonson MG, Junglen S, Klempa B, Klingstrom J, Kou C, Laenen L, Lambert AJ, Langevin SA, Liu D, Lukashevich IS, Luo T, Lu CW, Maes P, de Souza WM, Marklewitz M, Martelli GP, Matsuno K, Mielke-Ehret N, Minutolo M, Mirazimi A, Moming A, Muhlbach HP, Naidu R, Navarro B, Nunes MRT, Palacios G, Papa A, Pauvolid-Correa A, Paweska JT, Qiao J, Radoshitzky SR, Resende RO, Romanowski V, Sall AA, Salvato MS, Sasaya T, Shen S, Shi XH, Shirako Y, Simmonds P, Sironi M, Song JW, Spengler JR, Stenglein MD, Su ZY, Sun S, Tang S, Turina M, Wang B, Wang C, Wang HL, Wang J, Wei TY, Whitfield AE, Zerbini FM, Zhang J, Zhang L, Zhang YF, Zhang YZ, Zhang Y, Zhou X, Zhu L, and Kuhn JH

Abstract

In February 2019, following the annual taxon ratification vote, the order Bunyavirales was amended by creation of two new families, four new subfamilies, 11 new genera and 77 new species, merging of two species, and deletion of one species. This article presents the updated taxonomy of the order Bunyavirales now accepted by the International Committee on Taxonomy of Viruses (ICTV).

Published
2019

39. Taxonomy of the order Bunyavirales: second update 2018

Author

Maes, P, Adkins, S, Alkhovsky, S, Avsic-Zupanc, T, Ballinger, M, Bente, D, Beer, M, Bergeron, E, Blair, C, Briese, T, Buchmeier, M, Burt, F, Calisher, C, Charrel, R, Choi, I, Clegg, J, de la Torre, J, de Lamballerie, X, Derisi, J, Digiaro, M, Drebot, M, Ebihara, H, Elbeaino, T, Ergunay, K, Fulhorst, C, Garrison, A, Gao, G, Gonzalez, J, Groschup, M, Gunther, S, Haenni, A, Hall, R, Hewson, R, Hughes, H, Jain, R, Jonson, M, Junglen, S, Klempa, B, Klingstrom, J, Kormelink, R, Lambert, A, Langevin, S, Lukashevich, I, Marklewitz, M, Martelli, G, Mielke-Ehret, N, Mirazimi, A, Muhlbach, H, Naidu, R, Nunes, M, Palacios, G, Papa, A, Paweska, J, Peters, C, Plyusnin, A, Radoshitzky, S, Resende, R, Romanowski, V, Sall, A, Salvato, M, Sasaya, T, Schmaljohn, C, Shi, X, Shirako, Y, Simmonds, P, Sironi, M, Song, J, Spengler, J, Stenglein, M, Tesh, R, Turina, M, Wei, T, Whitfield, A, Yeh, S, Zerbini, F, Zhang, Y, Zhou, X, Kuhn, J, Maes P, Adkins S, Alkhovsky SV, Avsic-Zupanc T, Ballinger MJ, Bente DA, Beer M, Bergeron E, Blair CD, Briese T, Buchmeier MJ, Burt FJ, Calisher CH, Charrel RN, Choi IR, Clegg JCS, de la Torre JC, de Lamballerie X, DeRisi JL, Digiaro M, Drebot M, Ebihara H, Elbeaino T, Ergunay K, Fulhorst CF, Garrison AR, Gao GF, Gonzalez JPJ, Groschup MH, Gunther S, Haenni AL, Hall RA, Hewson R, Hughes HR, Jain RK, Jonson MG, Junglen S, Klempa B, Klingstrom J, Kormelink R, Lambert AJ, Langevin SA, Lukashevich IS, Marklewitz M, Martelli GP, Mielke-Ehret N, Mirazimi A, Muhlbach HP, Naidu R, Nunes MRT, Palacios G, Papa A, Paweska JT, Peters CJ, Plyusnin A, Radoshitzky SR, Resende RO, Romanowski V, Sall AA, Salvato MS, Sasaya T, Schmaljohn C, Shi XH, Shirako Y, Simmonds P, Sironi M, Song JW, Spengler JR, Stenglein MD, Tesh RB, Turina M, Wei TY, Whitfield AE, Yeh SD, Zerbini FM, Zhang YZ, Zhou XP, Kuhn JH, Maes, P, Adkins, S, Alkhovsky, S, Avsic-Zupanc, T, Ballinger, M, Bente, D, Beer, M, Bergeron, E, Blair, C, Briese, T, Buchmeier, M, Burt, F, Calisher, C, Charrel, R, Choi, I, Clegg, J, de la Torre, J, de Lamballerie, X, Derisi, J, Digiaro, M, Drebot, M, Ebihara, H, Elbeaino, T, Ergunay, K, Fulhorst, C, Garrison, A, Gao, G, Gonzalez, J, Groschup, M, Gunther, S, Haenni, A, Hall, R, Hewson, R, Hughes, H, Jain, R, Jonson, M, Junglen, S, Klempa, B, Klingstrom, J, Kormelink, R, Lambert, A, Langevin, S, Lukashevich, I, Marklewitz, M, Martelli, G, Mielke-Ehret, N, Mirazimi, A, Muhlbach, H, Naidu, R, Nunes, M, Palacios, G, Papa, A, Paweska, J, Peters, C, Plyusnin, A, Radoshitzky, S, Resende, R, Romanowski, V, Sall, A, Salvato, M, Sasaya, T, Schmaljohn, C, Shi, X, Shirako, Y, Simmonds, P, Sironi, M, Song, J, Spengler, J, Stenglein, M, Tesh, R, Turina, M, Wei, T, Whitfield, A, Yeh, S, Zerbini, F, Zhang, Y, Zhou, X, Kuhn, J, Maes P, Adkins S, Alkhovsky SV, Avsic-Zupanc T, Ballinger MJ, Bente DA, Beer M, Bergeron E, Blair CD, Briese T, Buchmeier MJ, Burt FJ, Calisher CH, Charrel RN, Choi IR, Clegg JCS, de la Torre JC, de Lamballerie X, DeRisi JL, Digiaro M, Drebot M, Ebihara H, Elbeaino T, Ergunay K, Fulhorst CF, Garrison AR, Gao GF, Gonzalez JPJ, Groschup MH, Gunther S, Haenni AL, Hall RA, Hewson R, Hughes HR, Jain RK, Jonson MG, Junglen S, Klempa B, Klingstrom J, Kormelink R, Lambert AJ, Langevin SA, Lukashevich IS, Marklewitz M, Martelli GP, Mielke-Ehret N, Mirazimi A, Muhlbach HP, Naidu R, Nunes MRT, Palacios G, Papa A, Paweska JT, Peters CJ, Plyusnin A, Radoshitzky SR, Resende RO, Romanowski V, Sall AA, Salvato MS, Sasaya T, Schmaljohn C, Shi XH, Shirako Y, Simmonds P, Sironi M, Song JW, Spengler JR, Stenglein MD, Tesh RB, Turina M, Wei TY, Whitfield AE, Yeh SD, Zerbini FM, Zhang YZ, Zhou XP, and Kuhn JH

Abstract

In October 2018, the order Bunyavirales was amended by inclusion of the family Arenaviridae, abolishment of three families, creation of three new families, 19 new genera, and 14 new species, and renaming of three genera and 22 species. This article presents the updated taxonomy of the order Bunyavirales as now accepted by the International Committee on Taxonomy of Viruses (ICTV).

Published
2019

40. Surveillance in individuals with high multi-organ cancer risk.

Author

Pinese M., James P., Trainer A., Ferris N., Moodie K., Milner B., Young M., Tucker K., Thomas D., Harris M., Ballinger M., Silvestri A., Pinese M., James P., Trainer A., Ferris N., Moodie K., Milner B., Young M., Tucker K., Thomas D., Harris M., Ballinger M., and Silvestri A.

Abstract

Background: Comprehensive cancer risk management guidelines for individuals at high multi-organ cancer risk are lacking. Research studies support whole body MRI as part of a baseline surveillance assessment. Aim(s): To estimate the prevalence and incidence of investigable lesions in a high-risk population and investigate mutational signatures in peripheral blood as an early detection mechanism; and to assess the acceptability, psychosocial impact and cost effectiveness of the surveillance program. Method(s): The surveillance program includes annual whole-body MRI, physical examination, full blood evaluation, fecal occult blood testing, breast MRI and 2-5 yearly colonoscopy/endoscopy. Deep sequencing will be used to detect genetic signatures of malignancy in cell free plasma. Psychometric evaluations are undertaken and participants complete cost diaries. Medicare/PBS data is also utilized. Result(s): Since July 2013, 42 TP53 pathogenic variant carriers (25F, 17M; age 18-63 years) have been enrolled. After completion of 38 first-year whole body MRI scans, three new asymptomatic malignancies (lumbar liposarcoma, Gleason score 8 and 9 prostate cancers) have been detected. Second- and third-year whole body MRI scans (45 total) detected an additional four new primary cancers; thymic pleomorphic liposarcoma, pelvic chondrosarcoma, renal leiomyosarcoma and a pheochromocytoma. All other screening procedures have been normal. Mutational signatures of malignancy in the peripheral blood were detectable by sequencing. Preliminary psychosocial data indicate no lasting adverse effects. Conclusion(s): Evaluation of the surveillance schedule is ongoing. Detection of seven asymptomatic primary malignancies (treated with curative intent), in conjunction with the acceptability and lack of negative psychological impact supports evaluation over a longer term.

Published
2019

41. OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC

Author

Jotte, R., primary, Cappuzzo, F., additional, Vynnychenko, I., additional, Stroyakovskiy, D., additional, Abreu, D. Rodriguez, additional, Hussein, M., additional, Soo, R., additional, Conter, H., additional, Kozuki, T., additional, Huang, K., additional, Graupner, V., additional, Sun, S., additional, Hoang, T., additional, Jessop, H., additional, Mccleland, M., additional, Ballinger, M., additional, Sandler, A., additional, and Socinski, M., additional

Published
2019
Full Text
View/download PDF

43. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung carcinoma patients responding to atezolizumab treatment

Author

Fehlings, M., primary, Nardin, A., additional, Jhunjhunwala, S., additional, Kowanetz, M., additional, O'Gorman, B., additional, Hegde, P., additional, Li, J., additional, Sumatoh, H., additional, Lee, B., additional, Kim, L., additional, Flynn, S., additional, Ballinger, M., additional, Newell, E., additional, and Yadav, M., additional

Published
2019
Full Text
View/download PDF

44. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

Author

von Pawel, J., primary, Bordoni, R., additional, Satouchi, M., additional, Fehrenbacher, L., additional, Cobo, M., additional, Han, J.Y., additional, Hida, T., additional, Moro-Sibilot, D., additional, Conkling, P., additional, Gandara, D.R., additional, Rittmeyer, A., additional, Gandhi, M., additional, Yu, W., additional, Matheny, C., additional, Patel, H., additional, Sandler, A., additional, Ballinger, M., additional, Kowanetz, M., additional, and Park, K., additional

Published
2019
Full Text
View/download PDF

48. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

Author

Reinmuth, N, additional, Syrigos, K, additional, Mazieres, J, additional, Cortinovis, D, additional, Dziadziuszko, R, additional, Gandara, D, additional, Conkling, P, additional, Goldschmidt, J, additional, Thomas, CA, additional, Bordoni, R, additional, Kosty, M, additional, Braiteh, F, additional, Hu, S, additional, Ballinger, M, additional, Patel, H, additional, Gandhi, M, additional, and Fehrenbacher, L, additional

Published
2018
Full Text
View/download PDF

49. Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

Author

Rittmeyer, A, additional, Gandara, D, additional, Kowanetz, M, additional, Mok, T, additional, Fehrenbacher, L, additional, Fabrizio, D, additional, Otto, G, additional, Malboeuf, C, additional, Lieber, D, additional, Paul, SM, additional, Amler, L, additional, Riehl, T, additional, Schleifman, E, additional, Cummings, C, additional, Hegde, PS, additional, Zou, W, additional, Sandler, A, additional, Ballinger, M, additional, and Shames, DS, additional

Published
2018
Full Text
View/download PDF

50. Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

Author

Rittmeyer, A, additional, Gadgeel, S, additional, Kowanetz, M, additional, Zou, W, additional, Hirsch, FR, additional, Kerr, KM, additional, Gandara, D, additional, Barlesi, F, additional, Park, K, additional, McCleland, M, additional, Koeppen, H, additional, Ballinger, M, additional, Sandler, A, additional, and Hegde, PS, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results